



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

To,

Date: 07.12.2020

BSE Limited
P.J.Towers, Dalal Street
Mumbai - 400001

Dear Sir/Madam,

Sub: Annual Report for the Financial Year 2019-2020.

Ref: Scrip Code 538965

With reference to the subject cited,pursuant to Regulation 34 of SEBI (LODR) Regulations 2015, we are herewithenclosing the 25thAnnual Report for the Financial Year 2019-20.


This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully,
For Concord Drugs Limited

S. Koni Reddy

S. Koni Reddy
Whole-time Director & CFO
DIN: 02829319



Encl. as above.

CONCORD DRUGS LIMITED

**25th
ANNUAL REPORT
2019-20**

CONCORD DRUGS LIMITED

CORPORATE INFORMATION

Board of Directors

Mr. S. Nagi Reddy	: Chairman and Whole-time Director DIN: 01764665
Mr. T. Narsimha Reddy	: Managing Director DIN: 07538313
Mr. S. Koni Reddy	: Executive Director cum CFO DIN: 02829319
Ms. P. Chandra Kala	: Independent Director DIN: 07138391
Mr. K. Ramachandra Reddy	: Independent Director DIN: 02285257
Mr. P. Venkatram Reddy	: Independent Director DIN: 07001606

Company Secretary & Compliance Officer

Ms. Jyoti Goyal

Statutory Auditors

M/s. N G Rao & Associates
Chartered Accountants
Firm Registration No. 009399S
H.No: 6-3-1186/A/6,
2nd Floor, Chinna Balreddy Building,
Begumpet, Hyderabad- 500016

Secretarial Auditors

Vivek Surana & Associates
Practicing Company Secretaries
Hyderabad

Registered Office

Concord Drugs Limited.,
Survey No.249, Brahmanapally (V)
Hayatnagar (M), R.R.Dist-501511
Telangana, India.
Ph: 04024036379
Website: www.concorddrugs.in
Investor email: concorddrugsltd@gmail.com
CIN: L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Registrars and Share Transfer Agents

Aarathi Consultants Private Limited,
1-2-285, Domalaguda,
Hyderabad, Telangana-500029
Tel: 040-27634445
Fax: 040- 27632184
Email: info@aarthiconsultants.com
ISIN No. INE858L01010

Factory Locations

1. Survey No. 249, Brahmanapally (V),
Hayat Nagar (M), R R (D): 501511
2. Khasra No. 165/3, Nalhera Ananthapur,
Paragana Bhagwanpur, Tehsil Roorkee,
Haridwar (D), Uttaranchal.

Bankers

State Bank of India
Ramakrishna Puram, Kothapet, Hyderabad

Listed At : BSE Limited

CONCORD DRUGS LIMITED

NOTICE

Notice is hereby given that the 25th Annual General Meeting of the Shareholders of Concord Drugs Limited will be held on Tuesday, 29th day of December, 2020 at 12.30 P.M. through Video Conferencing/ Other Audio Visual Means (OAVM) to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2020 the Statement of Profit & Loss and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.
2. To appoint a director in place of S. Koni Reddy, who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

3. **RE-APPOINTMENT OF MRS. P. CHANDRAKALA (DIN: 07138391) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:**

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 160 and Schedule IV and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force, Articles of Association of the Company, and pursuant to recommendation of the Nomination and Remuneration Committee and the Board of Directors, the approval of the Members of the Company be and is hereby accorded for re-appointment of Mrs. P. Chandrakala (DIN 07138391) whose current period of office expires on 31st March 2020 and who has submitted a declaration confirming the criteria of Independence under Section 149(6) of the Companies Act, 2013 read with the Listing Regulations, as amended from time to time, and who is eligible for re-appointment for a second term under the provisions of the Companies Act, 2013, Rules made thereunder and Listing Regulations and whose term shall not be subject to retirement by rotation, to hold office for a term of 5 (five) consecutive years on the Board of the Company w.e.f. 01st April, 2020 up to 31st March, 2025."

"RESOLVED FURTHER THAT the Board be and is hereby authorized to approve the terms and conditions and to do all such acts, deeds, matters and things as may be considered necessary, appropriate and desirable to give effect to the Resolution."

CONCORD DRUGS LIMITED

4. REAPPOINTMENT OF MR NAGI REDDY SEELAM AS WHOLETIME DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass, with or without modification(s) the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 196,197 read with Schedule V and any other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or reenactment thereof for the time being in force and Articles of Association of the Company, the consent of the members of the company be and is hereby accorded to reappoint Mr. Nagi Reddy Seelam (DIN: 01764665) Whole-time Director for a period of three years with effect from 30.05.2020 to 29.05.2023 at a remuneration of Rs.1,50,000 p.m. and the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc., within such prescribed limits in terms of Schedule V of the Companies Act, 2013, as amended from time to time.”

“RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during her tenure the Company shall pay to Mr. Nagi Reddy Seelam, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time”.

“RESOLVED FURTHER THAT the Board be and is hereby authorized to approve the terms and conditions including any changes in remuneration and to do all such acts, deeds, matters and things as may be considered necessary, appropriate and desirable to give effect to the resolution.”

5. REAPPOINTMENT OF MR THATIREDDY NARSIMHA REDDY AS MANAGING DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass, with or without modification(s) the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 196,197 read with Schedule V and any other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or reenactment thereof for the time being in force and Articles of Association of the Company, the consent of the members of the company be and is hereby accorded to reappoint Mr. Thati Reddy Narsimha Reddy (DIN: 07538313) Managing Director for a period of three years with effect from 16.02.2020 to 15.02.2023 at a remuneration of Rs. 1,50,000 p.m. and the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc., within such prescribed limits in terms of Schedule V of the Companies Act, 2013, as amended from time to time.”

CONCORD DRUGS LIMITED

“RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during her tenure the Company shall pay to Mr. Thatireddy Narsimha Reddy, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time”.

“RESOLVED FURTHER THAT the Board be and is hereby authorized to approve the terms and conditions including any changes in remuneration and to do all such acts, deeds, matters and things as may be considered necessary, appropriate and desirable to give effect to the resolution.”

6. APPOINTMENT AND PAYMENT OF REMUNERATION TO THE COST AUDITOR FOR THE FINANCIAL YEAR 2020-2021:

To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification (s) or re-enactment thereof, for the time being in force), consent of the Members be and is here by accorded for appointment of M/s. KJU & Associates (Registration No.000474), Cost Accountants to conduct the audit of the cost records of the Company for the financial year ended 31st March, 2021 on a remuneration of Rs. 35000/- (Rupees thirty five thousand only) plus out of pocket expenses and applicable taxes.”

“RESOLVED FURTHER THAT the Board is hereby authorized to take all necessary steps as may be necessary to give effect to the above resolution including filing of all such necessary documents as may be required in this regard.”

**For and on behalf of the Board
For Concord Drugs Limited**

**Sd/-
S. Nagi Reddy
Chairman
(DIN: 01764665)**

**Place: Hyderabad
Date : 04.12.2020**

CONCORD DRUGS LIMITED

NOTES:

1. In view of the continuing Covid-19 pandemic, the Ministry of Corporate Affairs (“MCA”) has vide its circular dated May 5, 2020 read with circulars dated April 8, 2020 and April 13, 2020 (collectively referred to as “MCA Circulars”) permitted the holding of the Annual General Meeting (“AGM”) through VC / OAVM, without the physical presence of the Members at a common venue. In compliance with the provisions of the Companies Act, 2013 (“Act”), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and MCA Circulars, the AGM of the Company is being held through VC / OAVM.
2. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
3. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting’s agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who

CONCORD DRUGS LIMITED

are allowed to attend the AGM without restriction on account of first come first served basis.

5. The attendance of the Members (members logins) attending the e-AGM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.concordrugs.in
7. The Notice can also be accessed from the website of the Stock Exchange i.e. BSE Limited at www.bseindia.com. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. www.evotingindia.com.
8. Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 relating to the Special Business in the Notice is annexed hereto and forms part of this Notice.
9. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the directors are interested under Section 189 of the Companies Act, 2013, will be available for inspection at the AGM.
10. Shareholders holding shares in physical form may write to the company/company's R&T agents for any change in their address; shareholders holding shares in electronic form may inform the same to their depository participants immediately, where applicable.
11. The Register of Members and Share Transfer Books of the Company will remain closed from 23.12.2020 to 29.12.2020 (Both days inclusive).
12. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.
13. Corporate Members are requested to send to the Company's Registrar & Transfer Agent, a duly certified copy of the Board Resolution authorizing their representative to attend and vote at the Annual General Meeting.
14. Recent regulations require submission of Aadhar/PAN number by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit Aadhar card/PAN details to the

CONCORD DRUGS LIMITED

Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their Aadhar card/PAN details to the Company/ Registrar and Share Transfer Agents.

15. Since securities of the Company are traded compulsorily in dematerialized form as per SEBI mandate, members holding shares in physical form are requested to get their shares dematerialized at the earliest.
16. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send the relevant share certificates to M/s Aarthi Consultants Pvt. Ltd., Share Transfer Agents of the Company for their doing the needful.
17. Members are requested to send their queries at least 10 days before the date of meeting so that information can be made available at the meeting.
18. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the company and correspond with them directly regarding share transfer/transmission /transposition, Demat / Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
19. In terms of Section 72 of the Companies Act, 2013, a member of the company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
20. In compliance with the aforesaid MCA Circulars and SEBI Circular dated May 12, 2020, Notice of the AGM along with the Annual Report 2019-20 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/Depositories.
21. Members may also note that the Notice of the 25th Annual General Meeting and the Annual Report for 2019- 20 will also be available on the Company's website www.concorddrugs.in for their download. For any communication, the shareholders may also send requests to the Company's investor email id: concorddrugsltd@gmail.com.
22. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.

CONCORD DRUGS LIMITED

23. Instructions for e-voting and joining the agm are as follows:

A. THE INTRUCTIONS FOR SHAREHOLDRES FOR REMOTE E-VOTING ARE AS UNDER:

- I. In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Members are provided with the facility to cast their vote electronically, through the e-voting services provided by Central Depository Services (India) Limited (CDSL) on all the resolutions set forth in this Notice. The instructions for e-voting are given herein below.
- II. The remote e-voting period commences on 26th day, December 2020 (9:00 a.m. IST) and ends on 28th day, December, 2020 (5:00 p.m. IST). During this period, Members holding shares either in physical form or in dematerialized form, as on 22nd day, December, 2020 i.e. cut-off date, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter. Those Members, who will be present in the AGM through VC / OAVM facility and have not cast their vote on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.
- III. The Members who have cast their vote by remote e-voting prior to the AGM may also attend/ participate in the AGM through VC / OAVM but shall not be entitled to cast their vote again. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
- IV. The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date.
- V. The details of the process and manner for remote e-voting are explained herein below:
 - (i) The shareholders should log on to the e-voting website www.evotingindia.com.
 - (ii) Click on Shareholders tab.
 - (iii) Now Enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,

CONCORD DRUGS LIMITED

- b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
- c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
- (iv) Next enter the Image Verification as displayed and Click on Login.
- (v) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- (vi) If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	<p>Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none">• Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field.• In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
Dividend Bank Details OR Date of Birth (DOB)	<p>Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <ul style="list-style-type: none">• If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iv).

- (vii) After entering these details appropriately, click on “SUBMIT” tab.
- (viii) Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to

CONCORD DRUGS LIMITED

vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- (ix) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (x) Click on the EVSN for the relevant <Concord Drugs Limited> on which you choose to vote.
- (xi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xiii) After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiv) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xvi) If a demat account holder has forgotten the changed password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvii) Shareholders can also cast their vote using CDSL’s mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.

B. INSTRUCTIONS FOR SHAREHOLDERS FOR E-VOTING DURING THE AGM ARE AS UNDER:

- (i) The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.

CONCORD DRUGS LIMITED

- (ii) Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
- (iii) If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility , then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

C. NOTE FOR NON – INDIVIDUAL SHAREHOLDERS AND CUSTODIANS:

- (i) Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporates.
- (ii) A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- (iii) After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- (iv) The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- (v) A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- (vi) Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer at the email address viveksurana24@gmail.com and to the Company at the email address [viz; concorddrugsltd@gmail.com](mailto:concorddrugsltd@gmail.com), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

CONCORD DRUGS LIMITED

D. PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL ADDRESSES ARE NOT REGISTERED WITH THE DEPOSITORIES FOR OBTAINING LOGIN CREDENTIALS FOR E-VOTING:

- (i) For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
- (ii) For Demat shareholders -, please provide Demat account details (CDSL-16 digit beneficiary ID or NSDL-16 digit DPID + CLID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to Company/RTA email id.
- (iii) The company/RTA shall co-ordinate with CDSL and provide the login credentials to the above mentioned shareholders.

E. INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

- (i) Shareholder will be provided with a facility to attend the EGM/AGM through VC/OAVM through the CDSL e-Voting system. Shareholders may access the same at <https://www.evotingindia.com> under shareholders/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVSN of Company will be displayed.
- (ii) Shareholders are encouraged to join the Meeting through Laptops / iPads for better experience.
- (iii) Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- (iv) Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 5 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at company email id viz; concorddrugsltd@gmail.com. The shareholders

CONCORD DRUGS LIMITED

who do not wish to speak during the AGM but have queries may send their queries in advance 5 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.

(v) Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

1. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com or call 1800225533.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call 1800225533.

24. Relevant documents referred to in the accompanying Notice, as well as Annual Report and are open for inspection at the Registered Office of the Company, during the office hours, on all working days between 10.00 A.M. to 5.00 P.M. up to the date of Annual General Meeting.
25. The voting rights of shareholders shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date (record date) of 22.12.2020.
26. M/s. Vivek Surana & Associates, Practicing Company Secretaries, has been appointed as the Scrutinizer to scrutinize the e-voting process in accordance with the law. The Scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and make, not later than 48 hours of conclusion of the AGM, a consolidated Scrutinizer’s Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same.

The Results declared along with the Scrutinizer’s Report shall be placed on the Company’s website [www. http://www.concorddrugs.in](http://www.concorddrugs.in) and on the website of CDSL within two (2) days of passing of the resolutions at the AGM of the Company and communicated BSE Limited.

CONCORD DRUGS LIMITED

27. The Ministry of Corporate Affairs (vide circular nos. 17/2011 and 18/2011 dated April 21 and April 29, 2011 respectively), has undertaken a 'Green Initiative in Corporate Governance' and allowed companies to share documents with its shareholders through an electronic mode. Members are requested to support this green initiative by registering/uploading their email addresses, in respect of shares held in dematerialized form with their respective Depository Participant and in respect of shares held in physical form with the Company's Registrar and Share Transfer Agents.

**For and on behalf of the Board
For Concord Drugs Limited**

**Sd/-
S. Nagi Reddy
Chairman
(DIN: 01764665)**

**Place: Hyderabad
Date : 04.12.2020**

CONCORD DRUGS LIMITED

EXPLANATORY STATEMENT

(Pursuant to Section 102 of the Companies Act, 2013)

ITEM NO.3:

REAPPOINTMENT OF MRS. P. CHANDRAKALA (DIN: 07538313) AS INDEPENDENT DIRECTOR OF THE COMPANY:

Mrs. P. Chandrakala Kala (DIN: 07538313) was appointed as Independent Director of the Company for a period of 5 years i.e. upto 31.03.2020 at the 20th Annual General Meeting held on 30.09.2015.

Mrs. P. Chandrakala Kala term as an Independent Director of the company ended on 31.03.2020. In terms of Section 149 and other applicable provisions of the Companies Act, 2013, Mrs. P. Chandrakala Kala being eligible and offering herself for re-appointment as an Independent Director for five consecutive years w.e.f. 01.04.2020 to 31.03.2025. The Company has received a notice from a member under Section 160 of the Companies Act 2013 for appointment of Mrs. P. Chandrakala Kala for the office of Director in Independent category.

In the opinion of the Board, Mrs. P. Chandrakala Kala fulfils the conditions specified in the Companies Act, 2013 and rules made thereunder for her appointment as an Independent Director of the Company. The Board considers that her continued association would be of immense benefit to the Company and it is desirable to continue to avail services of Mrs. P. Chandrakala Kala as an Independent Director.

Accordingly the Board of Directors recommends the passing of the above resolution as Special Resolution set out in the item no. 3 of the notice for appointment of Mrs. P. Chandrakala Kala.

Save and except Mrs. P. Chandrakala Kala Independent Director, being an appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

CONCORD DRUGS LIMITED

ITEM No.4

REAPPOINTMENT OF MR NAGI REDDY SEELAM AS WHOLETIME DIRECTOR OF THE COMPANY

Mr. Nagi Reddy Seelam (DIN: 01764665) was appointed as Whole-time Director of the Company for a period of 3 years i.e. upto 29.05.2020.

Based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on 13.02.2020, approved the re-appointment of Mr. Nagi Reddy Seelam (DIN: 01764665) as Whole-time Director of the Company for a term of three years commencing from 30.05.2020 to 29.05.2023 with a remuneration upto Rs. 1,50,000 p.m.

Accordingly the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 4 of the notice for reappointment of Mr. Nagi Reddy Seelam.

Save and except Mr. Nagi Reddy Seelam Whole-time Director (DIN: 01764665) being an appointee and Mr. S. Koni Reddy , Director, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

1	Nature of Industry : Pharmaceutical Industry			
2	Date or expected date of commencement of commercial: The Company started its commercial operations on 24.04.1995			
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable			
4	Financial performance based on given indications			
	Particulars	2019-20 (Rs. in lakhs)	2018-19 (Rs. in lakhs)	2017-18 (Rs. in lakhs)
	Turnover	5133.88	4807.72	5179.72
	Net profit/loss after Tax	32.82	40.70	32.42
5	Foreign investments or collaborations, if any: Not Applicable			

CONCORD DRUGS LIMITED

II. INFORMATION ABOUT THE APPOINTEE:

1.	Background Details: Mr. Nagi Reddy Seelam is Chairman and Whole-time Director of the Company and aged about 51 yrs. He is a Post Graduate. He has an experience of 25 Years in Pharma Industry.
2.	Past Remuneration: The remuneration drawn by Mr. Nagi Reddy Seelam, Whole-time Director is Rs. 100000 per month at present.
3.	Recognition or awards : -- Nil
4.	Job Profile and his suitability: Keeping the past record of Mr. Nagi Reddy Seelam in mind and his contribution towards the Company, it is proposed to re-appoint him as Whole-time Director of the Company.
5.	Remuneration proposed: As set out in the resolutions for the item No.4 the remuneration to Mr. Nagi Reddy Seelam, Whole-time Director has the approval of the Nomination and Remuneration Committee and Board of Directors, is within the limits specified under Schedule V of Companies Act.
6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin): Taking into consideration of the size of the Company, the profile of Mr. Nagi Reddy Seelam and the responsibilities shouldered by him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any: Besides the remuneration, he is holding 17,03,000 Equity Shares of the Company.

CONCORD DRUGS LIMITED

III. OTHER INFORMATION:

1. Reasons for inadequate profits: The Company is in the mode of expansion of the business which generally requires spending lot of money upfront leading to minimal profits in the initial years. All this expenditure will result in to revenues over a period of next two to three years.
2. Steps taken or proposed to be taken for improvement: Necessary efforts are being made to increase the clientele who in turn contribute for the growth of the business as well as the profitability.
3. Expected increase in productivity and profit in measurable terms:

The company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the company will improve considerably in the coming years.

ITEM No.5

REAPPOINTMENT OF MR THATIREDDY NARSIMHA REDDY AS MANAGING DIRECTOR OF THE COMPANY

Based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on 13.02.2020, approved the re-appointment of Mr. Thati Reddy Narsimha Reddy (DIN: 07538313) as Managing Director of the Company for a term of three years commencing from 16.02.2020 to 15.02.2023 with a remuneration upto Rs. 1,50,000 p.m.

Accordingly the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 5 of the notice for reappointment of Mr. Thati Reddy Narsimha Reddy

Save and except Thati Reddy Narsimha Reddy (DIN: 07538313), Managing Director being an appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Information in accordance with Schedule V of Companies Act, 2013

CONCORD DRUGS LIMITED

I. GENERAL INFORMATION

1	Nature of Industry : Pharmaceutical Industry			
2	Date or expected date of commencement of commercial: The Company started its commercial operations on 24.04.1995			
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable			
4	Financial performance based on given indications			
	Particulars	2019-20 (Rs. in lakhs)	2018-19 (Rs. in lakhs)	2017-18 (Rs. in lakhs)
	Turnover	5133.88	4807.72	5179.72
	Net profit/loss after Tax	32.82	40.70	32.42
5	Foreign investments or collaborations, if any: Not Applicable			

II. INFORMATION ABOUT THE APPOINTEE:

1.	Background Details: Mr. Thati Reddy Narsimha Reddy, Managing Director of the Company and aged about 54 yrs. He is a Graduate. He has an experience of 15 Years in Pharma Industry.
2.	Past Remuneration: Nil
3.	Recognition or awards : -- Nil
4.	Job Profile and his suitability: Keeping the past record of Mr. Thati Reddy Narsimha Reddy in mind and his contribution towards the Company, it is proposed to re-appoint him as Managing Director of the Company.
5.	Remuneration proposed: As set out in the resolutions for the item No.5 the remuneration to Mr. Thati Reddy Narsimha Reddy, Managing Director has the approval of the Nomination and Remuneration Committee and Board of Directors, is within the limits specified under Schedule V of Companies Act.

CONCORD DRUGS LIMITED

6.	<p>Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):</p> <p>Taking into consideration of the size of the Company, the profile of Mr. Thati Reddy Narsimha Reddy and the responsibilities shouldered by him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.</p>
7.	<p>Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:</p> <p>He is not holding any shares in the company</p>

III. OTHER INFORMATION:

1. Reasons for inadequate profits: The Company is in the mode of expansion of the business which generally requires spending lot of money upfront leading to minimal profits in the initial years. All this expenditure will result in to revenues over a period of next two to three years.
2. Steps taken or proposed to be taken for improvement: Necessary efforts are being made to increase the clientele who in turn contribute for the growth of the business as well as the profitability.
3. Expected increase in productivity and profit in measurable terms:

The company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the company will improve considerably in the coming years.

Item No. 6

The Board of Directors, on the recommendation of the Audit Committee, has approved the appointment of M/s. KJU & Associates (Registration No.000474), Cost Accountants as Cost Auditors of the Company for the financial year ending 31st March, 2021 to conduct the audit of cost records and fixed their remuneration at Rs. 35,000/- (Rupees thirty five thousand only) plus out of pocket expenses and applicable taxes etc.

As per the provisions of Section 148 of the Act read with the Companies Act,

CONCORD DRUGS LIMITED

2013 and as per the Rule 14 of Companies (Audit and Auditors) Rules, 2014, the appointment and remuneration payable to the Cost Auditors has to be approved by the shareholders of the Company.

Accordingly the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 6 of the notice for appointment and remuneration payable to the Cost Auditors for the financial year ending 31st March, 2021.

None of the Directors/ Key Managerial Personnel and their relatives of the Company is, in any way, concerned or interested, financially or otherwise in the above said Resolution.

**For and on behalf of the Board
For Concord Drugs Limited**

**Place: Hyderabad
Date : 04.12.2020**

**Sd/-
S. Nagi Reddy
Chairman
(DIN: 01764665)**

CONCORD DRUGS LIMITED

**Brief profile of the Directors seeking appointment
(Pursuant to Regulation 36(3) of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015)**

Name of the Director	Mrs. P. Chandrakala	Mr. Thati Reddy Narsimha Reddy
Date of Birth	02/06/1976	14/07/1966
Date of appointment	30/03/2015	16/07/2016
Qualification	B.Com	Graduation
Expertise in specific functional areas	Technical	Management
Names of the Listed entities in which the person is holding Directorships or Board Committee Memberships	Nil	Nil
No. of Shares held in the Company	-	-
Inter se relationship with any Director	-	-

CONCORD DRUGS LIMITED

Name of the Director	Mr. S. Nagi Reddy	S. Koni Reddy
Date of Birth	15/10/1969	21/06/1989
Date of appointment	04/04/2003	30.03.2015
Qualification	M.Sc	Graduation
Expertise in specific functional areas	Overall management, planning and strategy	Technical
Names of the Listed entities in which the person is holding Directorships or Board Committee Memberships	Nil	Nil
No. of Shares held in the Company	1703000 Equity Shares	975000 Equity Shares
Inter se relationship with any Director	Father of Mr. S. Koni Reddy, Executive director & CFO of the company	Son of Mr. S. Nagi Reddy, Chairman and Wholetime Director

**For and on behalf of the Board
For Concord Drugs Limited**

**Sd/-
S. Nagi Reddy
Chairman
(DIN: 01764665)**

**Place: Hyderabad
Date : 04.12.2020**

CONCORD DRUGS LIMITED

BOARDS' REPORT

To the Members,

The Directors have pleasure in presenting before you the 25th Board's Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2020.

1. FINANCIAL SUMMARY/HIGHLIGHTS, OPERATIONS, STATE OF AFFAIRS:

The performance during the period ended 31st March, 2020 has been as under:

(Rs. In Lakhs)

Particulars	2019-2020	2018-2019
Revenue from Operations	5133.89	4807.72
Other Income	12.01	8.59
Profit/Loss Before Depreciation, finance costs, Exceptional Items and Tax expense	346.41	374.46
Less: Depreciation/Amortisation/Impairment	146.39	171.18
Profit/Loss before finance costs, exceptional items and Tax expense	200.02	203.28
Less: Finance Costs	154.37	159.30
Profit/Loss before Exceptional Items and Finance Costs	45.65	43.98
Add/(Less): Exceptional Items	Nil	Nil
Profit/Loss before tax expense	45.65	43.98
(Less): Tax Expense (Current & deferred)	12.82	3.27
Profit/(Loss) for the year (1)	32.83	40.70
Total Comprehensive Income/(Loss) (2)	Nil	Nil
Total (1+2)	32.83	40.70
Balance carried forward to balance sheet	32.83	40.70
Earnings per share	0.38	0.52

CONCORD DRUGS LIMITED

REVIEW OF OPERATIONS:

During the year, the Company has generated a revenue of Rs. 5133.89 lakhs and achieved a profit of Rs. 32.83 lakhs for the financial year 2019-20 as against the revenue of Rs. 4807.72 Lakhs and net profit of Rs. 40.70 lakhs for the previous year.

IMPACT OF COVID 19

The company has evaluated the impact of Corona Virus (COVID-19) on the operations and future economic activity of the company and based on its review and current indicators and future economic prospects, there is no significant impact on the business of the company or its operations.

However, in the initial days of Lockdown in March, the companies manufacturing activities were impacted to minimal extent as the majority of employees could not reach the factory location due to the restrictions on movement of manpower, unavailability of Transportation.

2. MATERIAL CHANGES AND COMMITMENTS:

There were no material changes and commitments affecting financial position of the company between 31st March and the date of Board's Report. (i.e. 27.06.2020)

3. CHANGE IN THE NATURE OF BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of Business.

4. DIVIDEND:

The Directors have not recommended any dividend for the year.

UNPAID / UNCLAIMED DIVIDEND:

There is no unpaid or unclaimed dividend with the company.

5. RESERVES:

The Company has not carried any amount to the reserves.

6. BOARD MEETINGS:

The Board of Directors duly met 7 (seven) times on 16.04.2019, 14.05.2019, 30.05.2019, 14.08.2019, 15.10.2019, 14.11.2019 and 13.02.2020 and in respect of which meetings, proper notices were given

CONCORD DRUGS LIMITED

and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.

7. REVISION OF FINANCIAL STATEMENTS

There was no revision of the financial statements for the year under review.

8. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The company has received declarations from Independent directors of the company to the effect that they are meeting the criteria of independence as provided in Sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

The Independent Directors have also confirmed that they have complied Company's Code of Conduct. In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

9. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/ CFO AND KEY MANAGERIAL PERSONNEL.

During the year, Mrs. P. Chandrakala was reappointed as Independent Director subject to the approval by shareholders of the company at the general meeting after considering the recommendations of the Nomination and Remuneration Committee. Mr. Thati Narsimha Reddy and Mr. S. Nagi Reddy were appointed as Managing Director and Wholetime Director respectively for the term of 3 years. Mr. S. Koni Reddy who was liable to rotation has offered himself for the Appointment.

During the year under review, the Company has resigned Ms. Monika Bhutada as Company Secretary and Compliance Officer at the Board meeting held on 16th April 2019. Ms. Jyoti Goyal was appointed as Company Secretary and Compliance Officer at the Board meeting held on 15th October 2019.

10. FAMILIARISATION PROGRAMMES:

The Company familiarises its Independent Directors on their

CONCORD DRUGS LIMITED

appointment as such on the Board with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, etc. through familiarisation programme. The Company also conducts orientation programme upon induction of new Directors, as well as other initiatives to update the Directors on a continuing basis. The familiarisation programme for Independent Directors is disclosed on the Company's website www.concorddrugs.in.

11. COMPOSITION OF AUDIT COMMITTEE:

- I. The Audit Committee of the Company is constituted in line with the provisions of Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 177 of the Companies Act, 2013.
 - II. The terms of reference of the Audit Committee include a review of the following:
 - Overview of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements reflect a true and fair position and that sufficient and credible information is disclosed.
 - Recommending the appointment and removal of external auditors, fixation of audit fee and also approval for payment for any other services.
 - Discussion with external auditors before the audit commences, of the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
 - Reviewing the financial statements and draft audit report including quarterly / half yearly financial information.
 - Reviewing with management the annual financial statements before submission to the Board, focusing on:
 1. Any changes in accounting policies and practices;
 2. Qualification in draft audit report;
 3. Significant adjustments arising out of audit;
 4. The going concern concept;
 5. Compliance with accounting standards;
 6. Compliance with stock exchange and legal requirements concerning
-

CONCORD DRUGS LIMITED

financial statements and

7. Any related party transactions

- Reviewing the company's financial and risk management's policies.
- Disclosure of contingent liabilities.
- Reviewing with management, external and internal auditors, the adequacy of internal control systems.
- Reviewing the adequacy of internal audit function, including the audit character, the structure of the internal audit department, approval of the audit plan and its execution, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit.
- Discussion with internal auditors of any significant findings and follow-up thereon.
- Reviewing the findings of any internal investigations by the internal auditors into the matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- Looking into the reasons for substantial defaults in payments to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
- Reviewing compliances as regards the Company's Whistle Blower Policy.
- reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments

III. The previous Annual General Meeting of the Company was held on 30.09.2019 and Chairman of the Audit Committee, attended previous AGM.

IV. The composition of the Audit Committee and the attendance of each member of the Audit Committee are given below:

During the financial year 2019-20, 4 (four) meetings of the Audit Committee were held on 30.05.2019, 14.08.2019, 14.11.2019, 13.02.2020 respectively.

CONCORD DRUGS LIMITED

The details of the composition of the Committee and attendance of the members at the meetings are given below:

Name	Designation	Category	No. of meetings held	No. of meeting attended
Ms. P. Chandra Kala	Chairman	NED(I)	4	4
Mr.S. Nagi Reddy	Member	ED	4	4
Mr. P. Venkat Ram Reddy	Member	NED(I)	4	4

NED (I): Non-Executive Independent Director

ED: Executive Director

V. NOMINATION & REMUNERATION COMMITTEE

Terms of reference:

The main term of reference of the Committee is to approve the fixation/revision of remuneration of the Managing Director/Whole Time Director of the Company and while approving:

- To take into account the financial position of the Company, trend in the industry, appointee's qualification, experience, past performance, past remuneration etc.
- To bring out objectivity in determining the remuneration package while striking a balance between the interest of the Company and the Shareholders.
- To identify persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down and to recommend to the Board their appointment and /or removal.
- To carry out evaluation of every Director's performance.
- To formulate the criteria for determining qualifications, positive attributes and independence of a Director, and recommend to the Board a policy, relating to the remuneration for the Directors, key managerial personnel and other employees.
- To formulate the criteria for evaluation of Independent Directors and the Board.
- To recommend/review remuneration of the Managing Director and Whole-time Director(s) based on their performance and defined

CONCORD DRUGS LIMITED

assessment criteria.

- recommend to the board, all remuneration, in whatever form, payable to senior management.

POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION AND OTHER DETAILS:

The assessment and appointment of Members to the Board is based on a combination of criterion that includes ethics, personal and professional stature, domain expertise, gender diversity and specific qualification required for the position. The potential Board Member is also assessed on the basis of independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI (LODR) Regulations, 2015.

In accordance with Section 178(3) of the Companies Act, 2013, and Regulation 19(4) of SEBI (LODR) Regulations, 2015, on the recommendations of the Nomination and Remuneration Committee, the Board adopted a remuneration policy for Directors, Key Management Personnel (KMPs) and Senior Management.

Remuneration Policy:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered, individual performance etc.

The details of remuneration paid to the Executive and Non-Executive Directors for the financial year 2019-20 are given below:

Mr. S. Nagi Reddy, Chairman and Mr. S. Koni Reddy, Executive Director have drawn a remuneration of Rs. 12,00,000 p.a. and Rs. 12,00,000 p.a. for the year ended 31.03.2020 respectively.

None of the Directors is drawing any Commission, Perquisites, Retirement benefits etc.

During the year, the committee met on 16.04.2019, 30.05.2019, 15.10.2019 and 13.02.2020.

CONCORD DRUGS LIMITED

The details of composition of the Committee are given below:

Name	Designation	Category	No. of meetings held	No. of meeting attended
Ms. P. Chandra Kala	Chairman	NED(I)	4	4
Mr.S. Nagi Reddy	Member	ED	4	4
Mr. P. Venkat Ram Reddy	Member	NED(I)	4	4

NED (I): Non-Executive Independent Director

ED: Executive Director

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

- 2.1 "Director" means a director appointed to the Board of a Company.
- 1.2 "Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and reg. 19 of SEBI (Listing Obligation and Disclosure Requirement), Regulations, 2015.
- 2.3 "Independent Director" means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(1) (b) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

Qualifications and criteria

- 3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.

CONCORD DRUGS LIMITED

3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:

- General understanding of the company's business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the Companies Act, 2013;
- shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the company for Directors and senior Management personnel;
- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as may be prescribed, from time to time, under the Companies Act, 2013, SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the company's business.

3.2 Criteria of Independence

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or

CONCORD DRUGS LIMITED

relationships are disclosed by a Director.

3.2.2 The criteria of independence shall be in accordance with guidelines as laid down in Companies Act, 2013 and reg. 16(1) (b) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3.2.3 The Independent Director shall abide by the “Code for Independent Directors” as specified in Schedule IV to the companies Act, 2013.

10.3 Other Directorships/ Committee Memberships

3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as Director of the company. The NR Committee shall take into account the nature of, and the time involved in a Director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

3.3.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

3.3.3 A Director shall not serve an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

3.3.4 A Director shall not be a member in more than 10 committee or act chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder’s relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the Companies Act, 2013 shall be excluded.

Remuneration policy for Directors, key managerial personnel and other employees

1. Scope:

1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the directors, key managerial personnel and other

CONCORD DRUGS LIMITED

employees of the company.

2. Terms and Reference:

In this policy the following terms shall have the following meanings:

- 2.1 “Director” means a Director appointed to the Board of the company.
- 2.2 “key managerial personnel” means
- (i) The Chief Executive Office or the managing director or the manager;
 - (ii) The company secretary;
 - (iii) The whole-time director;
 - (iv) The chief finance Officer; and
 - (v) Such other office as may be prescribed under the companies Act, 2013
- 2.3 “Nomination and Remuneration Committee” means the committee constituted by Board in accordance with the provisions of section 178 of the companies Act, 2013 and reg. 19 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

- 3.1 Remuneration to Executive Director and Key Managerial Personnel
- 3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall approved by the shareholders.
- 3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.
- 3.1.3 The Remuneration structure to the Executive Director and key managerial personnel shall include the following components:
- (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Commission (Applicable in case of Executive Directors)
 - (iv) Retiral benefits

CONCORD DRUGS LIMITED

(v) Annual performance Bonus

3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

3.2 Remuneration to Non – Executive Directors

3.2.1 The Board, on the recommendation of the Nomination and Remuneration Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per provisions of the companies act.

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof.

3.3. Remuneration to other employees

3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

VI. STAKEHOLDERS RELATIONSHIP COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name	Designation	Category	No. of meetings held	No. of meeting attended
Ms. P. Chandra Kala	Chairman	NED(I)	1	1
Mr. S. Nagi Reddy	Member	ED	1	1
Mr. P. Venkat Ram Reddy	Member	NED(I)	1	1

NED (I): Non-Executive Independent Director

ED: Executive Director

CONCORD DRUGS LIMITED

B) Powers:

The Committee has been delegated with the following powers:

- To redress shareholder and investor complaints relating to transfer of shares, Dematerialization of Shares, non-receipt of Annual Reports, non-receipt of declared dividend and other allied complaints.
- To approve, transfer, transmission, and issue of duplicate / fresh share certificate(s)
- Consolidate and sub-division of share certificates etc.
- To redress, approve and dispose off any, other complaints, transactions and requests etc., received from any shareholder of the company and investor in general.

The Board has delegated the power to process the transfer and transmission of shares to the Registrar and Share Transfer Agents, who process share transfers within a week of lodgement in the case of shares held in physical form.

The Company has designated an exclusive e-mail ID called concorddrugsltd@gmail.com for complaints/grievances.

VII. RISK MANAGEMENT COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name	Designation	Category	No. of meetings held	No. of meeting attended
Ms. P. Chandra Kala	Chairman	NED(I)	-	-
Mr. S. Nagi Reddy	Member	ED	-	-
Mr. P. Venkat Ram Reddy	Member	NED(I)	-	-

NED (I): Non-Executive Independent Director

ED: Executive Director

CONCORD DRUGS LIMITED

B) RISK MANAGEMENT POLICY:

The Company follows a comprehensive system of Risk Management. The Company has adopted a procedure for assessment and minimization of probable risks. It ensures that all the risks are timely defined and mitigated in accordance with the well-structured risk management process.

12. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

Vigil Mechanism Policy has been established by the Company for directors and employees to report genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013 and Regulation 22 of SEBI(LODR), Regulations 2015. The same has been placed on the website of the Company.

13. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

- (a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) The Directors had prepared the annual accounts on a going concern basis; and
- (e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CONCORD DRUGS LIMITED

14. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES:

The Company does not have any subsidiaries/associates/joint ventures.

15. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

The Company does not have any subsidiaries/associates. During the year neither any Company became its subsidiary nor ceased to be its Subsidiary.

16. INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

The Company is not required to transfer any amount to IEPF pursuant to Section 125 of the Companies Act, 2013 and Rules made thereof.

17. EXTRACT OF ANNUAL RETURN:

As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an extract of annual return in MGT 9 is a part of this Annual Report in enclosed as **Annexure-I**.

18. STATUTORY AUDITORS:

M/s. N G Rao & Associates, Chartered Accountants, were appointed as Statutory Auditors of the company in the 1/2018 Extra ordinary general meeting held on 24th day of August, 2018 to fill the casual vacancy caused by the resignation of M/s. MM Reddy & Co., Chartered Accountants, Hyderabad and who holds office upto the conclusion of 28th Annual General Meeting.

19. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT:

There have been no frauds reported by the auditors' u/s 143(12).

20. SECRETARIAL AUDIT:

Pursuant to the provisions of Section 134(3) (f) & Section 204 of the Companies Act, 2013, the Board has appointed M/s. Vivek Surana & Associates, Practicing Company Secretaries has under taken Secretarial Audit of the Company for financial year ending 31.03.2020.

CONCORD DRUGS LIMITED

The report of the Secretarial Auditor is enclosed herewith vide Annexure-II of this Report.

21. QUALIFICATIONS IN AUDIT REPORTS:

Explanations or comments by the Board on every qualification, reservation or adverse remark or disclaimer made—

(a) Statutory Auditors Report:

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the year ended March 31, 2020 and has noted that the same does not have any reservation, qualification or adverse remarks. However, the Board decided to further strengthen the existing system and procedures to meet all kinds of challenges and growth in the market expected in the coming years.

(b) Secretarial Audit Report:

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31, 2020 on the Compliances according to the provisions of section 204 of the Companies Act 2013, and the same does not have any reservation, qualifications or adverse remarks except the following:

1. Non filing of Form DIR - 12 with ROC pertaining to the appointment of Independent Directors in the AGM held on 30.09.2019 and
2. Delay in filing of Listing Application with BSE Ltd. BSE has levied penalty for the same.

Reply: Reply: The Company has noted the observations and is in the process of complying the same.

22. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134 (3) (m) of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

CONCORD DRUGS LIMITED

B. Technology Absorption:

1. Research and Development (R&D): NIL
2. Technology absorption, adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

Foreign Exchange Earnings: NIL

Foreign Exchange Outgo: NIL

23. DETAILS RELATING TO DEPOSITS, COVERING THE FOLLOWING:

The Company has not accepted any deposits falling within the meaning of Sec.73, 74 & 76 of the Companies Act, 2013 read with the Rule 8(v) of Companies (Accounts) Rules 2014, during the financial year under review. Further, there are no deposits which are not in compliance with the requirements of Chapter V of the Companies Act, 2013.

24. SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS:

During the period under review there were no significant and material orders passed by the regulators or Courts or Tribunals impacting the going concern status and the company's operations in future.

25. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Company has well established procedures for internal control across its various locations, commensurate with its size and operations. The organization is adequately staffed with qualified and experienced personnel for implementing and monitoring the internal control environment. The internal audit function is adequately resourced commensurate with the operations of the Company and reports to the Audit Committee of the Board.

The Board has appointed M/s. PCN & Associates., Chartered Accountants, Hyderabad as Internal Auditors in its meeting held 14.08.2019 for the year 2019-20. Summary of significant Audit observations along with recommendations and its implementations are reviewed by the Audit committee and concerns, if any, are reported to Board.

26. INSURANCE:

The properties and assets of your Company are adequately insured.

CONCORD DRUGS LIMITED

27. RISK MANAGEMENT POLICY:

The Company follows a comprehensive system of Risk Management. The Company has adopted a procedure for assessment and minimization of probable risks. It ensures that all the risks are timely defined and mitigated in accordance with the well-structured risk management process.

28. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The company has not given loans, Guarantees or made any investments covered under section 186 of Companies Act, 2013 during the year under review.

29. CREDIT & GUARANTEE FACILITIES:

The Company is availing Credit and Guarantee Facilities from State Bank of India, Dilsukhnagar Branch.

30. SHARE CAPITAL

The authorised share capital of the Company stands at Rs. 11,00,00,000/- divided into 1,10,00,000 equity shares of Rs.10/- each.

The paid up share capital of the Company stands at Rs. 8,74,37,500 /- divided into 87,43,750 equity shares of Rs.10/- each.

31. COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY:

Since the Company does not have the net worth of Rs. 500 Crore or more, or turnover of Rs. 1000 Crore or more, or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

32. RELATED PARTY TRANSACTIONS:

All contracts/arrangements/transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on arm's length basis. There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large.

CONCORD DRUGS LIMITED

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in nature.

Transactions with the Related Parties as required under Indian Accounting Standard-18 are disclosed in Note 2.4 of the standalone financial statements forming part of this Annual Report

33. POLICIES

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website (www.concorddrugs.in). The policies are reviewed periodically by the Board and updated based on need and new compliance requirement.

34. DISCLOSURE ABOUT COST AUDIT:

The Company is in due compliance with the Companies (Cost Records and Audit) Rules, 2014. M/s KJU & Associates, Cost Accountants is the Cost Auditors of the Company.

35. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1)(2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014, the ratio of remuneration of Mr. Nagi Reddy Chairman & Whole-time Director & Mr. Koni Reddy (Director cum CFO) to median employees is 9.09:1 & 9.09:1 time respectively.

36. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

Since the paid-up capital of the Company is less than Rs. 10 Crores and Net worth of the Company is less than Rs. 25 Crores, Corporate Governance as envisaged in SEBI (LODR) Regulations is not applicable.

37. SECRETARIAL STANDARD

The Company is in compliance with the applicable secretarial standards SS1 and SS2

CONCORD DRUGS LIMITED

38. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC):

There is no application filed for corporate insolvency resolution process, by a financial or operational creditor or by the company itself under the IBC before the NCLT

39. EVENT BASED DISCLOSURES

During the year under review, the Company has taken up any of the following activities:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by company or giving of loans by it for purchase of its shares: NA
5. Buy back shares: NA
6. Disclosure about revision: NA
7. Preferential Allotment: However the Company has allotted 882000 equity shares on at par to the promoters and others on preferential Basis on 14.05.2019 on conversion of warrants.

40. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

41. CEO/ CFO Certification

The Managing Director and CFO certification of the financial statements for the year 2019-20 is annexed in this Annual Report.

42. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of

CONCORD DRUGS LIMITED

Section 197(12) of the Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as Annexure III to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as Annexure IV.

During the year NONE of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act, 2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

43. BOARD EVALUATION:

Pursuant to the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, the Board has carried out an Annual Evaluation of its own performance, performance of the Directors and the working of its Committees. The Board's functioning was evaluated on various aspects, including inter alia degree of fulfilment of key responsibilities, Board structure and composition, establishment and delineation of responsibilities to various Committees, effectiveness of Board processes, information and functioning.

Evaluation of the Committees performance was based on the criteria like composition, its terms of the reference and effectiveness of committee meetings, etc., Individual Director's performance evaluation is based on their preparedness on the issues to be discussed, meaningful and constructive discussions and their contribution to the Board and Committee meetings. The Chairperson was evaluated mainly on key aspects of his role. These performance exercises were conducted seeking inputs from all the Directors / Committee Members wherever applicable.

The evaluation procedure followed by the company is as mentioned below:

- i) Feedback is sought from each Director about their views on the performance of the Board, covering various criteria such as degree of fulfilment of key responsibilities, Board structure and composition, establishment and delineation of responsibilities to various Committees, effectiveness of Board processes, information and functioning, Board culture and dynamics, quality of relationship between the Board and the Management and efficacy of communication with external stakeholders.

CONCORD DRUGS LIMITED

Feedback was also taken from every Director on his assessment of the performance of each of the other Directors.

- ii) The Nomination and Remuneration Committee (NRC) then discusses the above feedback received from all the Directors.
- iii) Based on the inputs received, the Chairman of the NRC also makes a presentation to the Independent Directors at their meeting, summarising the inputs received from the Directors as regards Board performance as a whole and of the Chairman. The performance of the Non-Independent Non-Executive Directors and Board Chairman is also reviewed by them.
- iv) Post the meeting of the Independent Directors, their collective feedback on the performance of the Board (as a whole) is discussed by the Chairman of the NRC with the Chairman of the Board. It is also presented to the Board and a plan for improvement is agreed upon and is pursued.
- v) Every statutorily mandated Committee of the Board conducts a self-assessment of its performance and these assessments are presented to the Board for consideration. Areas on which the Committees of the Board are assessed include degree of fulfilment of key responsibilities, adequacy of Committee composition and effectiveness of meetings.
- vi) Feedback is provided to the Directors, as appropriate. Significant highlights, learning and action points arising out of the evaluation are presented to the Board and action plans are drawn up. During the year under report, the recommendations made in the previous year were satisfactorily implemented.

The peer rating on certain parameters, positive attributes and improvement areas for each Board member are also provided to them in a confidential manner. The feedback obtained from the interventions is discussed in detail and, where required, independent and collective action points for improvement are put in place.

44. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING

The Company has also adopted a code of conduct for prevention of Insider trading. All directors, senior management employees and other employees who are having access to the unpublished price sensitive information of the company are governed by the code. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company, as well as the consequences of violation. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

CONCORD DRUGS LIMITED

During the year under the review there has been due compliance with the code of conduct for prevention of insider trading. The code of conduct for prevention of insider trading is available in the company's website www.concorddrugs.in

45. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees are covered under this policy. The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints at the beginning of the year: Nil
- No. of complaints received: Nil
- No. of complaints disposed off: Nil

46. DETAILS OF PENALTIES IMPOSED BY THE REGULATORY AUTHORITIES

During the year under review, BSE has levied the penalty for delay in filing the application for the listing approval of 8,82,000 equity shares and the company is yet to pay the penalty.

47. INVESTOR EDUCATION AND PROTECTION FUND

No amounts and/or shares were transferred to the Investor Education and Protection Fund during the year under review.

48. DISCLOSURE ON CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE.

No corporate insolvency resolution process was initiated under the provisions of Insolvency and Bankruptcy Code during the year under review.

49. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed to its social responsibility. The Company has been

CONCORD DRUGS LIMITED

taking utmost care in complying with all pollution control measures from time to time strictly as per the directions of the Government.

We would like to place on record our appreciation for the efforts made by the management and the keen interest shown by the Employees of your Company in this regard.

50. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects

51. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation appended as Annexure V for information of the Members.

52. ACKNOWLEDGEMENTS:

The Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company.

The Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company for their continued support for the growth of the Company.

**For and on behalf of the Board
For Concord Drugs Limited**

**Sd/-
S. Nagi Reddy
Chairman
(DIN: 01764665)**

**Sd/-
T. Narsimha Reddy
Managing Director
(DIN: 07538313)**

**Place: Hyderabad
Date : 27.06.2020**

CONCORD DRUGS LIMITED

Certificate of Code of Conduct for the year 2019-20

To

The shareholders

Concord Drugs Limited

Code of Conduct

The Company has formulated and implemented a Code of Conduct for Board Members and Senior Management of the Company. Requisite annual affirmations of compliance with the respective Codes have been made by the Directors and Senior Management of the Company.

Certificate of Code of Conduct for the year 2019-2020 as per Regulation 17(5) read with Regulation 34 (3) Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Concord Drugs Limited is committed for conducting its business in accordance with the applicable laws, rules and regulations and with highest standards of business ethics. The Company has adopted a "Code of Ethics and Business Conduct" which is applicable to all Director, officers and employees.

I hereby certify that all the Board Members and Senior Management have affirmed the compliance with the Code of Ethics and Business Conduct, under a certificate of Code of Conduct for the year 2019-20

**For and on behalf of the Board
For Concord Drugs Limited**

**Place: Hyderabad
Date : 27.06.2020**

**Sd/-
S. Nagi Reddy
Chairman
(DIN: 01764665)**

CONCORD DRUGS LIMITED

CERTIFICATE BY THE MANAGING DIRECTOR AND CFO OF THE COMPANY

To

The Board of Directors

Concord Drugs Limited

Dear Sirs,

As required under Regulation 17(8) read with Part B, Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we state that:

1. We have reviewed the financial statements and the cash flow statement for the year ended 31st March 2020 and to the best of our knowledge and belief;
 - a. These statements do not contain any materially untrue statement nor omit any material fact nor contain statements that might be misleading, and
 - b. These statements present a true and fair view of the company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violative of the company's code of conduct.
3. We accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the company and I have disclosed to the auditors and the audit committee, deficiencies in the design or the operation of internal controls, if any, of which I was aware and the steps that I have taken or propose to take and rectify the identified deficiencies and,
4. That we have informed the auditors and the audit committee of:
 - a) Significant changes in the internal control during the year;
 - b) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c) Instances of significant fraud of which we have become aware and the involvement of any employee having a significant role in the company's internal control system.

For and on behalf of the Board
Concord Drugs Limited

Place: Hyderabad
Date: 27.06.2020

Sd/-
T. Narsimha Reddy
Managing Director

Sd/-
S. Koni Reddy
Director & CFO

CONCORD DRUGS LIMITED

DISCLOSURE WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

As per Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company hereby discloses the details of unpaid/unclaimed dividend and the respective share thereof as follows:

Aggregate No. of Shareholders and the outstanding shares in the suspense account at the beginning of the year.	No. of shareholders who approached the company for transfer of shares from suspense account during the year.	No. of shareholders to whom shares were transferred from suspense account during the year.	Aggregate No. of Shareholders and the outstanding shares in the suspense account at the end of the year.
NIL	NIL	NIL	NIL

*** Voting Right on these shares shall remain frozen till the rightful owner of such shares claims the shares.*

Note: The Company has never declared dividends since its inception and therefore there is no amount lying in unpaid/unclaimed dividend account.

CONCORD DRUGS LIMITED

ANNEXURE-I

MGT 9

Extract of Annual Return

As on the Financial Year 31.03.2020

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS					
i.	CIN	L24230TG1995PLC020093			
ii.	Registration Date	24/04/1995			
iii.	Name of the Company	Concord Drugs Limited			
iv.	Category / Sub-Category of the Company	Company limited by Shares/Non-govt company			
v.	Address of the Registered office and contact details	Survey No.249, Brahmanapally Village HayatnagarMandal ,R. R District 501511,Telangana			
vi.	Whether listed company Yes / No	Yes			
vii.	Name, Address and Contact details of Registrar and Transfer Agent, if any	Aarathi Consultants Pvt. Ltd,1-2-285, Domalaguda,Hyderabad,Telangana,500029, Tel: 040-27634445 Fax: 040-27634445 Email: info@aarthiconsultants.com			
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:					
All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-					
Sl. No.	Name and Description of main products /services	NIC Code of the Product / service	% to total turnover of the company		
1	Pharmaceuticals	2423	100.0		
III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:					
S.No.	Name and Address of the Company	CIN/GLN	Holding/Subsidiary /Associate	% of shares held	Applicable Section
	The Company does not have any subsidiaries.				
IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)					

CONCORD DRUGS LIMITED

i) *Category-wise Share Holding;-*

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year			%Change during the year	
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
Individual/ HUF	30,58,500	0	30,58,500	38.41	30,58,500	6,82,000	37,40,500	42.78	4.27
Central Govt.	--	--	--	--	--	--	--	--	--
State Govt (s)	--	--	--	--	--	--	--	--	--
Bodies Corp.	--	--	--	--	--	--	--	--	--
Banks / FI	--	--	--	--	--	--	--	--	--
Any Other....	--	--	--	--	--	--	--	--	--
Sub-total (A) (1) :-	30,58,500	0	30,58,500	38.41	30,58,500	6,82,000	37,40,500	42.78	4.27
(2) Foreign									
a) NRIs - Individuals	--	--	--	--	--	--	--	--	--
b) Other – Individuals	--	--	--	--	--	--	--	--	--
c) Bodies Corp.	--	--	--	--	--	--	--	--	--
d) Banks / FI	--	--	--	--	--	--	--	--	--
e) Any Other....	--	--	--	--	--	--	--	--	--
Sub-total (A) (2):-	--	--	--	--	--	--	--	--	--

CONCORD DRUGS LIMITED

Total shareholding of Promoter (A) = (A)(1)+(A)(2)	30,58,500	0	30,58,500	38.41	30,58,500	6,82,000	37,40,500	42.78	4.27
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	--	--	--	--	--	--	--	--	--
b) Banks / FI	--	--	--	--	--	--	--	--	--
c) Central Govt	--	--	--	--	--	--	--	--	--
d) State Govt(s)	--	--	--	--	--	--	--	--	--
e) Venture Capital Funds	--	--	--	--	--	--	--	--	--
f) Insurance Companies	--	--	--	--	--	--	--	--	--
g) FIs	--	--	--	--	--	--	--	--	--
h) Foreign Venture Capital Fund	--	--	--	--	--	--	--	--	--
Sub-total (B1)	--	--	--	--	--	--	--	--	--
2. Non Institutions									
a) Bodies Corp.									
i) Indian	76552	0	76552	0.97	14849	0	14849	0.17	(0.80)
ii) Overseas	--	--	--	--	--	--	--	--	--
b) Individuals									

CONCORD DRUGS LIMITED

i) Individual shareholders holding nominal share capital up to Rs. 1 lakh	1449747	557000	2006747	25.53	1456965	555000	1911965	21.87	1.45
ii) Individual shareholders holding nominal share capital in excess of Rs 1lakh	2803062	0	2803062	35.65	2639446	402700	3042146	32.50	0.05
c) Others (specify)									
1. NRI	35569	0	35569	0.45	34049	0	34049	0.39	(0.06)
2. Clearing Members	13425	0	13425	0.17	241	0	241	0.00	(0.17)
Sub-total (B)(2):-	3966898	759800	4726698	60.12	4045550	957700	5003250	57.22	0.31
Total Public Shareholding (B)=(B)(1)+(B)(2)	4043450	759800	48,03,250	61.10	4045550	957700	5003250	57.22	0.31
C. Shares held by Custodian for GDRs & ADRs	--	--	--	--	--	--	--	--	--
Grand Total (A+B+C)	72,90,150	571600	78,61,750	100	7104050	1639700	87,43,750	100.00	--

CONCORD DRUGS LIMITED

(ii) Shareholding of Promoters								
Sl. No.	Shareholder's Name	No. of Shares held at the beginning of the year			No. of Shares held at the end of the year			%Change during the year
		No. of shares	% of Total Shares of the company	% of shares pledged/encumbered to total shares	No. of shares	% of Total Shares of the company	% of shares pledged/encumbered to total shares	
1.	S.Nagi Reddy	14,13,000	17.98	--	17,03,000	19.48	--	1.50
2.	S.Koni Reddy	7,97,000	10.14	--	9,75,000	11.15	--	1.01
3.	Vundela Ramasubba Reddy	3,97,500	5.06	--	3,97,500	5.06	--	0.00
4.	S. Manoj Kumar Reddy	4,51,000	5.74	--	6,65,000	7.61	--	1.87
(iii) Change in Promoters' Shareholding (please specify, if there is no change): No Change								
Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year				
		No. of Shares	% of total shares of the company	No. of shares	% of total shares of the company			
1	S. Nagi Reddy	1413000	17.97					
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	Increase in shareholding : conversion of shares into warrants 290000	1.51					
	At the End of the year	--	--	1703000	19.48			
2	S. Koni Reddy	797000	10.14					
	Date wise Increase / Decrease in	Increase in	1.01					

CONCORD DRUGS LIMITED

	Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	shareholding : conversion of shares into warrants 178000			
	At the End of the year	--	--	9,75,000	11.15
3	S. Manoj Kumar Reddy	451000	5.74		
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	Increase in shareholding : conversion of shares into warrants 214000	1.87	--	--
	At the End of the year	--	--	6,65,000	7.61
4	Vundela Ramasubba Reddy	3,97,500	5.06		
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	--	--	--	--
	At the End of the year			3,97,500	5.06

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No	Name of Shareholder	Shareholding at the beginning of the year		Date	Increase/ Decrease in shareholding	Reason	Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the Company				No. of Shares	% of total Shares of the Company
1.	P. Lakshmi	-	-	14.05.2019	200000	2.29	200000	2.29
2	Rajender Kumar Agarwal	167633	2.13		--	--	167633	2.13
				20.12.2019	1000	purchase	168633	
3	Puttaha Mahesh Kumar	166000	2.11		--	--	166000	2.11

CONCORD DRUGS LIMITED

4	Sushil Kumar Agarwal	130400	1.66	--	--	--	130400	1.66
5	Manju Agarwal	130140	1.65	--	--	--	130140	1.65
6	Sanivarapu Jhansi	125560	1.60	--	--	--	125560	1.60
7.	S.N. Thulasi Devi	121200	1.54	--	--	--	121200	1.54
8	Sannuthi Lokesh	100000	1.27	--	--	--	100000	1.27
9	Chandra mounika Sannuthi	100000	1.27	--	--	--	100000	1.27
10	Rakesh K	100000	1.27	--	--	--	100000	1.27

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	For Each of the Directors and KMP	Shareholding at the beginning of the year		Cummulative Share Holding during the year	
		No. of Shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Mr. S. Nagi Reddy				
	At the beginning of the year	1413000	17.97		
	Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):	Increase in shareholding : conversion of shares into warrants 290000	1.51		
	At the End of the year	--	--	1703000	19.48
2	S. Koni Reddy	797000	10.14		
	At the beginning of the year	Increase in shareholding : conversion of shares into warrants 178000	1.01		
	Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons	--	--	9,75,000	11.15

CONCORD DRUGS LIMITED

	for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):				
	At the End of the year	1413000	17.97		
3.	Mr. K. Ramachandra Reddy				
	At the beginning of the year	50000	0.69		
	Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):		--	--	--
	At the End of the year	--	--	50000	0.69
4.	Mr. P. Venkatram Reddy	--	--	--	--
	At the beginning of the year	--	--	--	--
	Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):		--	--	--
	At the End of the year	--	--	--	--
6.	Ms. P. Chandra Kala	--	--	--	--
	At the beginning of the year	--	--	--	--
	Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):		--	--	--
	At the End of the year	--	--	--	--
7.	Mr. T. Narsimha Reddy	--	--	--	--
	At the beginning of the year	--	--	--	--
	Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):		--	--	--
	At the End of the year	--	--	--	--

CONCORD DRUGS LIMITED

V. INDEBTEDNESS				
Indebtedness of the Company including interest outstanding/accrued but not due for payment				
Indebtedness at the beginning of the financial year	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Principal Amount	97,963,838	5,731,354	--	103,695,192
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	97,963,838	5,731,354	--	103,695,192
Change in Indebtedness during the financial year	(4,511,056)	1,050,926	--	(3,460,130)
Addition				
Reduction				
Net Change	(4,511,056)	1,050,926	--	(3,460,130)
Indebtedness at the end of the financial year	93,452,782	6,782,280	--	100,235,062
i) Principal Amount				
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	93,452,782	6,782,280	--	100,235,062
VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL				
A. Remuneration to Managing Director, Whole-time Directors and/or Manager:				
Sl. no.	Particulars of Remuneration	Mr. S. Nagi Reddy	Mr. S. Koni Reddy	Total Amount
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income tax Act, 1961	Remuneration to managing Director 1200000	Remuneration to Whole-time Director 1200000	24,00,000
2.	Stock Option	--		--
3.	Sweat Equity	--		--
4.	Commission - as % of profit - Others, specify...	--		--
5.	Others, please specify	--		--
	Total (A)	12,00,000	12,00,000	24,00,000
	Ceiling as per the Act	60,00,000	60,00,000	--

CONCORD DRUGS LIMITED

B. Remuneration to other directors:						
Sl. no.	Particulars of Remuneration	Name of Director			Total Amount	
1.	Independent Directors Fee for attending board / committee meetings · Commission · Others, please specify	--	--	--	--	--
	Total (1)	--	--	--	--	--
2.	Other Non-Executive Directors · Fee for attending board / committee meetings · commission · Others, please specify	--	--	--	--	--
	Total (2)	--	--	--	--	--
	Total (B)=(1+2)	--	--	--	--	--
	Total Managerial Remuneration	--	--	--	--	--
	Overall Ceiling as per the Act	--	--	--	--	--
C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD						
Sl. no.	Particulars of Remuneration	Key Managerial Personnel				
		CEO	Company Secretary	CFO	Total	
			Jyoti Goyal	S. Koni Reddy		
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	--	137500	--	1,37500	
2.	Stock Option					
3.	Sweat Equity					
4.	Commission - as % of profit - others, specify...					
5.	Others, please Specify					
6.	Total	--	137500		137500	

CONCORD DRUGS LIMITED

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:					
Type	Section of the Companies Act	Brief Description	Details of Penalty /	Authority [RD / NCLT	Appeal made,
			Punishment/ Compounding fees imposed	/ COURT]	if any (give Details)
A. COMPANY					
Penalty	--	--	--	--	--
Punishment	--	--	--	--	--
Compounding	--	--	--	--	--
B. DIRECTORS					
Penalty	--	--	--	--	--
Punishment	--	--	--	--	--
Compounding	--	--	--	--	--
C. OTHER OFFICERS IN DEFAULT					
Penalty	--	--	--	--	--
Punishment	--	--	--	--	--
Compounding	--	--	--	--	--

FORM MR-3

SECRETARIAL AUDIT REPORT

**(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration Personnel)
Rules, 2014**

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2020

To,

The Members

Concord Drugs Limited

We have conducted the audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Concord Drugs Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2019 and ended 31st March, 2020, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made herein after:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st of March, 2020 according to the provisions of:
 - (i) The Companies Act, 2013 (the Act) and the rules made there under;
 - (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;

CONCORD DRUGS LIMITED

- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment and External Commercial Borrowings;
2. Compliance status in respect of the provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI ACT') is furnished hereunder for the financial year 2019-20:-
- i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **Complied with yearly and event based disclosures.**
 - ii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. www.concorddrugs.in.**
 - iii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **The Company has applied for the listing approval of 8,82,000 equity shares with delay and consequently has levied a penalty on the company for the same and the company is yet to pay the penalty and complete the listing and trading formalities.**
 - iv. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
 - v. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 and SEBI (Issue and Listing of Debt Securities) (Amendment) Regulations, 2019; **Not Applicable as the Company has not issued any debt securities during the year under review.**
 - vi. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However the company has Aarthi Consultants Private Limited, as its Share Transfer Agent.**

CONCORD DRUGS LIMITED

- vii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 and SEBI (Delisting of Equity Shares) (Amendment) Regulations, 2018; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
- viii. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
- ix. Other applicable laws include the following:
 - a. Drugs and Cosmetics Act, 1940 and amendments thereto from time to time.
 - b. Drugs and Cosmetics Rules, 1945
 - c. Pharmacy Act, 1948
 - d. Narcotic Drugs and Psychotropic Substances Act, 1985
 - e. Patents Act, 1970
 - f. Essential Commodities Act, 1995
 - g. National Pharmaceutical Policy, 2012
 - h. Labour Laws (wages, bonus, provident fund, gratuity etc)
 - i. Environment Protection Act, 1986
 - j. The Payment of Gratuity Act, 1972
 - k. Employees Provident Fund and Miscellaneous Provisions Act, 1952
 - l. Employees State Insurance Act, 1948

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

CONCORD DRUGS LIMITED

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above including the following:

- a) During the year the Company has conducted 7 meetings of the Board of Directors, 4 meetings of the Audit committee, 1 Meeting of Stakeholder Relationship Committee, 4 meeting of Nomination & Remuneration committee and 1 meeting of Independent Directors. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.
- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that
 - (i) the provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
 - External Commercial Borrowings were not attracted to the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was not attracted to the company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
 - (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- The Company has a CFO, Mr. S. Koni Reddy.
- The Company has a Company Secretary, Ms. Jyoti Goyal
- The Company has internal auditors namely M/s. PCN and Associates, Chartered Accountants.
- The website of the Company contains policies as specified by SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015 and the provisions of Companies Act, 2013

CONCORD DRUGS LIMITED

- The Board of Directors of the Company is duly constituted and have proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- The company has appointed Mr. P. Venkat Ram Reddy and Mr. P. Rama Chandra Reddy as Directors of the Company in the AGM held on 30.09.2019. However, the company has not filed the form DIR - 12 with Registrar of Companies.
- Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.
- We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- We further report that during the year under report, the Company has not undertaken event/action having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.
- The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed thoroughly in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

For Vivek Surana & Associates

Sd/-
Vivek Surana
Proprietor

Place: Hyderabad
Date: 27.06.2020

C.P.No: 12901, M.No. 24531
UDIN: A024531B000388730

CONCORD DRUGS LIMITED

Annexure A

To

The Members of

Concord Drugs Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Vivek Surana & Associates

Sd/-

Vivek Surana
Proprietor

Place: Hyderabad
Date: 27.06.2020

C.P.No: 12901, M.No. 24531
UDIN: A024531B000388730

CONCORD DRUGS LIMITED

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso there to

1. Details of contracts or arrangements or transactions not at arm's length basis -NIL
 - a. Name(s) of the related party and nature of relationship
 - b. Nature of contracts/arrangements/transactions
 - c. Duration of the contracts / arrangements/transactions
 - d. Salient terms of the contracts or arrangements or transactions including the value, if any
 - e. Justification for entering into such contracts or arrangements or Transactions date(s) of approval by the Board
 - f. Amount paid as advances, if any:
 - g. Date on which the special resolution was passed in general meeting as required under first proviso to section 188
2. Details of material contracts or arrangement or transactions at arm's length basis: NIL

CONCORD DRUGS LIMITED

ANNEXURE-V

STATEMENT SHOWING DETAILS AS PER RULE 5 OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

Rule 5 (1) Of The Companies (Appointment And Remuneration Of Managerial Personnel) Rules, 2014

S.No.	Particulars	Details
1.	The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.	The ratio of remuneration of Mr. Nagi Reddy Chairman & Whole-time Director & Mr. Koni Reddy (Director cum CFO) to median employees is 9.09:1 & 9.09:1 respectively times.
2.	The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.	NIL
3.	The percentage increase in the median remuneration of employees in the financial year.	2.5%
4.	The number of employees on the rolls of the company.	128
5.	Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration.	NIL
6.	Affirmation that the remuneration is as per the remuneration policy of the company.	Yes

CONCORD DRUGS LIMITED

ANNEXURE-IV

Statement showing the names of the Top ten Employees in terms of Remuneration drawn as per Rule 5 (3) Of The Companies (Appointment And Remuneration Of Managerial Personnel) Rules, 2014

S No	Name of the Employee	Designation of the employee	Remuneration received	Nature of employment whether contractual or otherwise	Qualification and experience of the employee	Date of commencement of employment	The age of the employee	The last employment held by such employee before joining the Company	The percentage of equity shares held by the employee in the Company within the meaning of clause (iii) of sub rule (2) of rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules,2014 .	Whether any such employee is a relative of any director or manager of the Company and if so, name of such director or manager
1	Ravindra babu Sutar	Production Manager(Pellets Division)	100000/-	Regular	B.Pharmacy	12.12.2016	56	Murali Krishna Pharma	NILL	NA
2	S.Manoj Kumar Reddy	Administration Manager	100000/-	Regular	M.B.A	01.04.2017	31	NA	NILL	NA
3	M. Rameswar Reddy	Production Manager(Liquids Division)	65000/-	Regular	B.Pharmacy	25.04.2017	53	Vilin Biomed Ltd	NILL	NA
4	V.Phani Sekhar	Production Manager(Tablets Division)	90000/-	Regular	B.Pharmacy	10.10.2016	52	Concord Drugs Ltd(Rooree)	NILL	NA
5	K.Krishna Prasad	Chemist(Production Tablets)	57500/-	Regular	B.Pharmacy	01.04.2013	45		NILL	NA
6	P. Ramachandrudu	Quality Control(Manager)	57500/-	Regular	B.Pharmacy	01.04.2013	43		NILL	NA
7	B.Venu Gopal Reddy	General Manager(Marketing)	80000/-	Regular	B.Pharmacy	03.08.2007	51	Darwin Formulations Pvt Ltd	NILL	NA
8	P. Rama krishna	Manager(Procurement)	45000/-	Regular	M.B.A	01.04.2013	35	Vance & Health	NILL	NA
9	G.Muthyam Rao	Chemist(Production)	37500/-	Regular	B.Pharmacy	25.08.2012	40		NILL	NA
10	T.Sridhar Reddy	Chemist(Production)	35000/-	Regular	BSC	01.07.2010	50		NILL	NA

MANAGEMENT'S DISCUSSION & ANALYSIS REPORT**1. INDUSTRY STRUCTURE AND DEVELOPMENTS:**

India is the third largest Pharmaceutical market in Asia and is one of the major global generic drugs providers. India's domestic Pharmaceutical market is also growing year on year. India offers numerous opportunities for the Pharmaceutical industry. Along with enhanced medical infrastructure, risk in the treatment of Chronic diseases, improving health insurance coverage etc., will act as growth opportunities for the industry.

OPPORTUNITIES AND THREATS:

According to the government of India's own estimates, India ranks third worldwide for pharmaceutical production by volume and 13th by value. It accounts for about 10% of the world's production by volume and 1.5% by value. This apparent discrepancy points towards the relatively lower price of Indian pharmaceutical products, and the high demand they enjoy in the global market. A major supplier of affordable low-price drugs across the world, India's role as the "pharmacy of the world" is well acknowledged by experts.

As the novel coronavirus spread across countries, concern about the potential for disruption to the manufacture and distribution of pharmaceutical products has intensified. The Indian government is contemplating ways to encourage domestic manufacturing of APIs by creating a suitable ecosystem in the country. The FDA is working with the domestic manufacturer as to mitigate the shortage. FDA is trying to ensure that there is no shortage has been identified for products which cannot be replaced by others. Indian government is also planning on how to grow in the API sector in future.

SEGMENT-WISE OR PRODUCT-WISE PERFORMANCE:

During the year under review, the Company has recorded revenue of Rs. 5133.89 Lakhs and made a profit of Rs. 32.83 Lakhs against revenue of Rs. 4807.72Lakhs and net profit of Rs. 40.70 Lakhs in the previous financial year 2018-19.

OUTLOOK:

The outlook for emerging market economies is expected to broadly improve, though volatility in capital flow will remain a challenge.

CONCORD DRUGS LIMITED

The pharmacy sector in India is highly regulated, yet the sector suffers from circulation of substandard and counterfeit drugs which hampers the retail segment of the business. Measures are being taken by the pharmacy regulatory bodies of the country to control the menace as it hampers the revenue earning drastically. The government is also taking major initiatives to provide medicines at subsidized rates and distribution of medicines in the rural belt.

The pharmacy retail industry in India operates predominantly in the unorganized format and is currently having approximately 20 major players operating in organized format. However, most organized players are operative regionally and are far from having a pan India presence. A variety of value added services are being incorporated by the organized players to attract a larger market share and initiatives are being taken to engage customers in brand loyalty.

RISKS AND CONCERNS:

While the industry is seeing amazing growth, there is increasing focus on associated risks such as high compliance standards, government reform and pricing pressures, expiration of key drug patents, marketing practices, mergers and acquisitions, increasing litigations, and supply chain management.

Our risk management framework is intended to ensure that risks are identified in a timely manner. We have implemented an integrated risk management framework to identify, assess, prioritize, manage/mitigate, monitor and communicate the risk across the county.

Senior management personnel meet at regular intervals to identify various risks, assess, and prioritize the risks. After due deliberations, appropriate strategies are made for managing/mitigating the risks. The company takes the help of independent professional firms to review the risk management structure and implementation of risk management policies. Audit Committee on a quarterly basis, review the adequacy and effectiveness of the risk management strategies, implementation of risk management/mitigation policies, it advises the board on matters of significant concerns for Redressal.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The Company maintains a system of well-established policies and procedures for internal control of operations and activities, and these are continually reviewed for effectiveness.

The internal control system is supported by qualified personnel and a continuous program of internal audit. The prime objective of such audits is to

CONCORD DRUGS LIMITED

test the adequacy and effectiveness of all internal control systems laid down by the management and to suggest improvements. We believe that the company's overall system of internal control is adequate given the size and nature of operations and effective implementation of internal control self-assessment procedures and ensure compliance to policies, plans and statutory requirements.

The internal control system of the company is also reviewed by the Audit Committee periodically. The Management duly considers and takes appropriate action on the recommendations made by the statutory auditors, internal auditors and the independent Audit Committee.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

The Financial performance of the company is already discussed elsewhere in the Annual Report.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED:

During the year under review the company has taken HR initiatives to train and develop talent pool. The company has also taken up a root cause analysis on bringing down the attrition rates. In order to improve the performance of management and to scale up the business operations, the company has recruited experienced personnel at senior level apart from strengthening other departments with competent people.

Details of changes in key financial ratios:

- (i) Debtors Turnover : 1.39:1
- (ii) Inventory Turnover : 2.43:1
- (iii) Interest Coverage Ratio : 1.30 : 1
- (iv) Current Ratio : 1.47:1
- (vi) Operating Profit Margin (%) = 0.01
- (vii) Net Profit Margin (%) = 0.01

Details of any change in return on net worth as compared to the immediately previous financial year along with a detailed explanation thereof:

CONCORD DRUGS LIMITED

There is change in return on net worth as compared to the immediately previous financial year.

2. DISCLOSURE OF ACCOUNTING TREATMENT:

The Company has not carried out any treatment different from that prescribed in Accounting Standards.

CAUTIONARY STATEMENTS:

Certain statements in the Management Discussion and Analysis describing the Company's objectives, predictions may be "forward-looking statements" within the meaning of applicable laws and regulations. Actual results may vary significantly from the forward looking statements contained in this document due to various risks and uncertainties. These risks and uncertainties include the effect of economic and political conditions in India, volatility in interest rates, new regulations and Government policies that may impact the Company's business as well as its ability to implement the strategy. The Company does not undertake to update these statements.

CONCORD DRUGS LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Concord Drugs Limited (“the Company”), which comprise the Standalone Balance Sheet as at 31 March 2020, and the Standalone Statement of Profit and Loss (including other comprehensive income), the statement of Changes in Equity and the statement of Cash flows for the year ended on that date, and a summary of the significant accounting policies and other Explanatory information (herein after referred to as “ the stand alone financial statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the accounting Standards prescribed under section 133 of the act read with the companies (Indian Accounting Standard s) Rules 2015 , as amended , (“Ind AS”) and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2020, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of standalone financial statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor’s Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Key Audit Matters

Key audit matters (‘KAM’) are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

CONCORD DRUGS LIMITED

We have determined the Matter Described below to be the key audit matters Communicated in Our report. We have fulfilled the responsibilities described in the auditor's responsibilities for the audit of standalone Ind As financial statements financial statements section of our reports including in relation to these matters. Accordingly our audit include the performance of procedures designed to respond to our assessment of risks of material mis statement of standalone Ind AS financial Statements the results of our audit Procedures , including the procedures prescribed to address the matters below provide the basis for our audit opinion on the accompanying standalone Ind AS Financial statements.

Key Audit Matter	Key Audit Matter
<p>Identification and disclosures of Related Parties</p> <p>1. The Company has related party transactions which include, amongst others, sale and purchase of goods/services to its subsidiaries, associates, joint ventures and other related parties and lending and borrowing to its subsidiaries, associates and joint ventures.</p> <p>2. We focused on identification and disclosure of related parties in accordance with relevant accounting standards as a key audit matter.</p>	<p>Our audit procedures amongst others included the following:</p> <p>1. Evaluated the design and tested the operating effectiveness of controls over identification and disclosure of related party transactions.</p> <p>2. Obtained a list of related parties from the Company's Management and traced the related parties to declarations given by directors, where applicable, and to Note 2.4 of the standalone Ind AS financial statements.</p> <p>3. Read minutes of the meetings of the Board of Directors and Audit Committee.</p> <p>4. Tested material creditors/debtors, loan outstanding/loans taken to evaluate existence of any related party relationships; tested transactions based on declarations of related party transactions given to the Board of Directors and Audit Committee.</p> <p>5. Evaluated the disclosures in the standalone Ind AS financial statements for compliance with Ind AS 24</p>

CONCORD DRUGS LIMITED

Information other than the Standalone Financial Statements and Auditor's Report thereon.

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the management Discussion and Analysis. Board's report including Annexures to the Board's Report Business Responsibility Report, Corporate Governance and Shareholders' Information, but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's and Board of Directors' Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management and the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process

CONCORD DRUGS LIMITED

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to standalone financial statements and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors in the standalone financial statements.

Conclude on the appropriateness of management's and Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our

CONCORD DRUGS LIMITED

audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under section 133 of the Act.
 - (e) On the basis of the written representations received from the directors as on 31 March 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2020 from being appointed as a director in terms of section 164(2) of the Act.
 - (f) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B"
 - (g) With respect to the other matters to be included in the Auditors report in accordance with the requirements of section 197(16) of the Act, As amended. In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the company to its directors during the year is in accordance with provisions of section 197 of the Act.
 - (h) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
-

CONCORD DRUGS LIMITED

- i. The Company has disclosed the pending litigations on its financial position in its standalone financial statements in Note No 2.2
 - ii. The Company has made provisions, as required under the applicable law or or Ind As or accounting standards, for material foreseeable losses, if any , on long-term contracts.
 - iii. There were no amounts which were required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. The disclosures in the standalone financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made in these standalone financial statements since they do not pertain to the financial year ended 31 March 2020.
2. As required by the Companies (Auditor's Report) Order 2016("the Order ") issued by the central Government in terms of Section 143 (11) of the Act, we give in Annexure A" a statement on the Matters Specified In Paragraphs 3 and 4 of the Order.

For N G Rao & Associates
Chartered Accountants
Firm Registration No: 009399S
UDIN: 2020730DAAAAIM3254

(G Nageswara Rao)
Partner
Membership No: 207300

Place : Hyderabad
Date: 27.06.2020

CONCORD DRUGS LIMITED

Annexure A to the Independent Auditors' Report

With reference to the Annexure A referred to in the Independent Auditors' Report to the members of the Company on the standalone financial statements for the year ended 31 March 2020, we report the following:

1. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment.

(b) The title deeds of the immovable Property are held in the name of the company.

(c) The Company has a regular programme of physical verification of its property, plant and equipment, by which all property, plant and equipment are verified in a phased manner over a period of three years. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, certain property, plant and equipment were physically verified during the year and no material discrepancies were noticed on such verification.
2. As informed by the company, the physical verification of inventory excluding Stock with third parties has been conducted at reasonable intervals by the management. However the physical verification report has not been shared with us.
3. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, limited liability partnerships or other parties covered in the register maintained under section 189 of the Act. Accordingly, the provisions of paragraph 3(iii) (a), (b) and (c) of the Order are not applicable to the Company
4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
5. The Company has not accepted any deposits from the public within the meaning of the directives issued by the Reserve Bank of India, provisions of sections 73 to 76 of the Act, any other relevant provisions of the Act and the relevant rules framed there under.

CONCORD DRUGS LIMITED

6. The central government has not prescribed the maintenance of cost records under section 148(1) of the act , for any of the services rendered by the company .
7. According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including Provident fund, Employees' State Insurance, Income-tax, Goods and Services tax, Duty of Customs, Cess and any other statutory dues have generally been regularly deposited during the year.
- b. According to the information and explanations given to us , no undisputed amounts payable in respect of provident fund , sales tax , wealth tax , duty of customs, value added tax cess and other material statutory dues were in arrears as at 31 march 2020.
- c. According to the information and explanations given to us , there are no material dues sales tax, service tax and value added tax , wealth tax , duty of customs and cess which have not been deposited with appropriate authorities on account of any dispute. However according to the information and explanations given to us, the following dues of income tax, have not been deposited by the company on account of disputes:

Particulars	Demand U/S	Period to which the amount relates	From Where the dispute is pending	Amount in Rs.	Previous Year	Present status
Income Tax Act,1961	143(3)	A.Y 2011-12	Assessing Officer	2,58,82,270	2,58,82,270	The case been remanded to the Assessing officer by the Income Tax Appellate Tribunal(ITAT), Hyderabad directing the AO to allow the deduction after his due verification. AO is yet to delete the addition vide order dated 31.01.2020
Income Tax Act,1961	143(3)	A.Y 2014-15	Assessing Officer	3,57,37,540	3,90,64,488	The case has been remitted back to AO for his verification and to delete the addition if he satisfies vide ITAT order dated 04/10/2019.

CONCORD DRUGS LIMITED

8. In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of loans or borrowings to banks. There are no dues to debenture holders during the year.
9. In our opinion and according to the information and explanations given to us, the Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, paragraph 3(ix) of the Order is not applicable to the Company.
10. To the best of our knowledge and according to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
11. In our opinion and according to the information and explanations given to us and based on examination of the records of the Company, the Company has paid/provided managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
12. According to the information and explanations given to us, in our opinion, the Company is not a Nidhi Company as prescribed under section 406 of the Act. Accordingly, paragraph 3(xii) of the Order is not applicable to the Company.
13. According to the information and explanations given to us and based on our examination of the records of the Company, all transactions with the related parties are in compliance with sections 177 and 188 of the Act, where applicable, and details of such transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.
14. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has made preferential allotment of shares during the year.

Details of Allotment of shares is as follows.

Name	No of Shares as on 31.03.2020	Shares as on 31.03.2019	Shares allotted
S.Nagi Reddy	17,03,000	14,13,000	2,90,000
S.Manoj Reddy	6,65,000	4,51,000	2,14,000
S.koni Reddy	9,75,000	7,97,000	1,78,000
Lakshmi Prasana	2,00,000	-	2,00,000
Total	35,43,000	26,61,000	8,82,000

CONCORD DRUGS LIMITED

15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable to the Company.
16. According to the information and explanations given to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934

For N G Rao & Associates
Chartered Accountants
Firm Registration No: 009399S
UDIN: 2020730DAAAAM3254

(G Nageswara Rao)
Partner
Membership No: 207300

Place : Hyderabad
Date: 27.06.2020

CONCORD DRUGS LIMITED

Annexure B to the Independent Auditors' report of event of event date on the financial statement of Concord Drugs Limited.

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

(Referred to in paragraph 1(A)(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

We have audited the internal financial controls with reference to standalone financial statements of Concord Drugs Limited ("the Company") as of 31 March 2020 in conjunction with our audit of the standalone financial statements of the Company for the year then ended.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to standalone financial statements and such internal financial controls were operating effectively as at 31 March 2020, based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the

CONCORD DRUGS LIMITED

audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls with Reference to Standalone Financial Statements

A company's internal financial controls with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to standalone financial statements include those policies and procedures that

(1) pertains to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of

CONCORD DRUGS LIMITED

unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Standalone Financial Statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial controls with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In Our Opinion, The Company has, in all material aspects, adequate internal financial controls System over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020 based on the internal control over financial reporting criteria established by the company considering the essential components of internal stated in the Guidance note on Audit of internal Financial controls Over Financial Reporting issued by the Institute of Chartered Accountant of India.

For N G Rao & Associates
Chartered Accountants
Firm Registration No: 009399S
UDIN: 2020730DAAAAIM3254

(G Nageswara Rao)
Partner
Membership No: 207300

Place : Hyderabad
Date: 27.06.2020

CONCORD DRUGS LIMITED

Balance sheet as at 31st March, 2020

Rs in Lakhs

Particulars	Note	As At March 31, 2020	As At March 31, 2019
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	973.86	1,106.32
(b) Capital Work-in Progress	3	99.77	28.89
(b) Investment property	3	78.60	78.60
Financial assets			
(a) Loans & Advances	5	53.62	50.02
Other Non current assets	4	39.29	39.26
Total Non - Current Assets		1,245.14	1,303.08
Current Assets			
Inventories	7	1,643.13	1,864.15
Financial assets			-
(a) Investments			-
(b) Trade receivables	6	2,544.60	4,843.47
(c) Cash and cash equivalents	8	1.21	15.89
(d) Bank balances other than (c) above	8	2.59	2.59
(e) Other Current Financial Assets	9	4.13	4.13
Other current assets	10	360.75	243.53
Total Current assets		4,556.40	6,973.77
Total Assets		5,801.55	8,276.85
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	874.38	786.18
Other equity	12	1,474.08	1,529.46
Total Equity		2,348.46	2,315.63
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	87.72	68.97
(b) Trade payables			
Deferred tax liabilities, net	14	13.70	12.79
Provisions	15	208.38	217.23
Government Grants	13	45.53	54.13
Total Non-current liabilities		355.34	353.13
Current liabilities			
Financial liabilities			
(a) Borrowings	16	869.10	913.68
(b) Trade payables	17	1,279.62	4,263.73
(c) Other Current financial liabilities	18	-	-
Current tax liabilities, net	15	11.91	11.72
Other current liabilities	19	937.13	418.96
Total Current liabilities		3,097.75	5,608.09
Total liabilities		3,453.09	5,961.22
Total Equity and liabilities		5,801.55	8,276.85

Corporate information and significant accounting policies 1 & 2

For N.G Rao and Associates
Chartered Accountants
FRN- 009399S

For and on behalf of the Board of Directors of
Concord Drugs Limited

G. Nageswara Rao
Partner
Mno-207300

Sd/-
S. Nagi Reddy
Chairman and Wholetime Director
DIN:01764665

Sd/-
Koni Reddy Seelam
Executive Director cum CFO
DIN: 02829319

Place: Hyderabad
Date: 27/06/2020

Sd/-
Jyoti Goyal
Company Secretary

CONCORD DRUGS LIMITED

Statement Of Standalone Profit and Loss for the year ended 31st March, 2020

Rs. In Lakhs

	Particulars	Note	As at March 31 2020	As at March 31, 2019
I	Revenue from Operations			
	a. Net sales from Operations	20	5,133.89	4,807.72
II	Other Income	21	12.01	8.59
III	Total Revenue (I+II)		5,145.89	4,816.31
IV	Expenses			
	a. Cost of Material Consumed	22	4,206.02	3,913.85
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	51.72	45.59
	c. Employees Benefit Expenses	24	350.72	252.92
	d. Finance Costs	25	154.37	159.30
	e. Depreciation and Amortisation expense	3	146.39	171.18
	f. Other expenses	26	191.03	229.50
	Total Expenses		5,100.25	4,772.33
	Profit/ (Loss) before Exceptional item and tax (III-IV)		45.65	43.98
V	Exceptional Items		-	0
VI	Profit/ (Loss) before tax (V-VI)		45.65	43.98
VII	Tax Expense:		12.82	3.27
VIII	a. Current tax		11.91	11.72
	b. Deferred tax charge/credit		0.91	-8.44
IX	Profit/ (Loss) for the period (VII-VIII)		32.83	40.70
X	Other Comprehensive Income		-	-
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		32.83	40.71
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		874.38	786.18
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.38	0.52
	b. Diluted (in Rs)		0.38	0.52

Corporate information and significant accounting policies 1 & 2

For N.G Rao and Associates
Chartered Accountants
FRN- 009399S

G. Nageswara Rao
Partner
Mno-207300

Place: Hyderabad
Date: 27/06/2020

For and on behalf of the Board of Directors of
Concord Drugs Limited

Sd/-
S. Nagi Reddy
Chairman and Wholetime Director
DIN:01764665

Sd/-
Koni Reddy Seelam
Executive Director cum CFO
DIN: 02829319

Sd/-
Jyoti Goyal
Company Secretary

CONCORD DRUGS LIMITED

Statement of Cash flow for the year ended 31st March, 2020

Particulars	Rs in Lakhs	
	As at March 31, 2020	As at March 31, 2019
A. CASH FLOW FROM OPERATING ACTIVITIES		
j	12.82	43.98
<i>Adjustments for:</i>		
Depreciation and amortisation expense	146.39	171.18
Finance costs	144.60	149.47
Interest income	(0.80)	(0.70)
Provision for Gratuity	-	
Operating profit before working capital changes	303.01	363.92
<i>Changes in working capital:</i> (Refer Note 40)		
<i>Adjustments for (increase) / decrease in operating assets:</i>		
Financial Assets		
Trade receivables	2,298.87	2,273.76
Loans and Advances	(3.60)	-
Other Non Current assets	(0.03)	(0.78)
Inventories	221.03	(2.22)
Other Current assets	(117.22)	(39.07)
Other bank balances		
Other Current financial Assets	-	8.58
<i>Adjustments for increase / (decrease) in operating liabilities:</i>		
Trade payables	(2,984.11)	(2,373.10)
Borrowings		
Other current financial liabilities	-	(121.06)
Other current liabilities		(25.86)
Current tax liabilities, net	0.19	44.07
Provisions	518.16	2.88
Deferred tax on amalgamation	-8.85	
Cash generated from operations	227.45	131.12
Net income tax paid	(11.91)	(11.72)
Net cash flow from operating activities (A)	215.55	119.40
B. CASH FLOW FROM INVESTING ACTIVITIES		
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	(84.82)	(34.00)
Proceeds from maturity of fixed deposits	-	(1.10)
- Others	0.80	0.70
Net cash (used in) / flow from investing activities (B)	(84.02)	(34.39)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity shares	88.20	-
Finance costs	(144.60)	(149.47)
Repayment of Borrowings	18.75	(271.88)
Repayment of short term Borrowings	(44.57)	13.16
Govt Grants	(8.61)	(7.61)
Other equity Adjustment	(55.37)	342.61
Net cash flow (used in) financing activities (C)	(146.21)	(73.19)
Net (decrease) in Cash and cash equivalents (A+B+C)	(14.68)	11.82
Cash and cash equivalents at the beginning of the year	15.89	4.08
Effect of exchange differences on translation of foreign currency Cash and cash equivalents	-	
Cash and cash equivalents at the end of the year (Refer Note (i) below)	1.21	15.89
* Comprises:		
Balances with Banks	0.08	9.66
Others	1.13	6.23
	1.21	15.89

For N.G Rao and Associates
Chartered Accountants
FRN- 009399S

G. Nageswara Rao
Partner
Mno-207300

Place: Hyderabad
Date: 27/06/2020

For and on behalf of the Board of Directors of
Concord Drugs Limited

Sd/-
S. Nagi Reddy
Chairman and Wholetime Director
DIN:01764665

Sd/-
Koni Reddy Seelam
Executive Director cum CFO
DIN: 02829319

Sd/-
Jyoti Goyal
Company Secretary

CONCORD DRUGS LIMITED

Notes to Financial Statements

1. Corporate information.

Concord Drugs Limited (“the Company”) the company was incorporated on 24th April , 1995. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. The company is Listed only in the India and operating from only one geographical location.

2. Basis of preparation and presentation and significant Accounting policies.

2.1 Basis of Preparation.

The financial statements are prepared in accordance with the Indian Accounting standards (Ind As),under historical cost convention on accrual basis except for certain financial instruments which are measured at fair values, the provisions of the companies Act.2013 (“the Act”) (to the extent notified) and guidelines issued by the Securities and Exchange board of India (SEBI). The Ind AS is prescribed under Section 133 of the Act. Read with Rule 3 of the companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules Issued thereafter.

2.1.1a Functional and presentation currency

The financial statements are presented in Indian Rupees (Rs.) which is also the company’s functional currency and the amounts have been rounded off to lakhs with two decimal places, unless otherwise stated.

2.1.b Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses and disclosure of contingent liabilities at the date of the financial statements. Actual results may differ from those estimates. Estimates and underlying assumption are reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively.

2.1.c Current and non-current classification:

The company presents assets and liabilities in the balance sheet

CONCORD DRUGS LIMITED

based on current/non-current classification.

An asset is current, when it satisfies any of the following criteria:

- It is expected to be realized or intended to sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realized within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

Current assets include the current portion of non-current financial assets. All other assets are classified as non-current.

A liability is current when it satisfies any of the following criteria:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

Current liabilities include the current portion of non-current financial liabilities. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

2.2. Significant Accounting Policies.

a. Inventories

Materials are valued at the lower of cost and estimated net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to affect the sale.

b. Revenue Recognition

Revenue is measured at the fair value of the consideration received or

CONCORD DRUGS LIMITED

receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates, Taxes and amounts collected on behalf of third parties.

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities as described below. The company bases its estimates on historical results, taking into consideration the type of customer, the type of transaction and the specifics of each arrangement.

Sale of Goods:

Revenue from sale of the goods are recognized when all the risks and rewards pertinent to the goods are transferred to the customer.

Interest Income:

Interest income is recognized as it accrues to the company using the effective interest rate method.

Dividend Income:

Dividend Income is recognized when the right to receive the dividend is established.

c. Property, plant and equipment

Freehold land is measured at historical cost at each reporting period. All other items of property, plant and equipment are stated at deemed value historical cost less accumulated depreciation and impairment losses, if any. On the transition to Ind AS the company has elected to measure at its historical cost as at 1st April 2016 and use that historical cost as its deemed cost on that date for property, plant and equipment. Historical cost includes expenditure that is directly attributable to the acquisition of the assets. The cost of the property, plant and equipment includes freight, installation cost, duties and non refundable taxes and other incidental expenses incurred during the acquisition, construction and installation of the respective assets. The company has not obtained the technical evaluation for recognizing the decommissioning cost of the property, plant and equipment installed.

Indirect expenditure including borrowing costs to the extent incidental to construction of property, plant and equipment incurred during the construction period will be allocated to the assets on commencement

CONCORD DRUGS LIMITED

of commercial of commercial production.

Cost of assets not ready for intended use as on the balance sheet date, is recognized as capital work-in-progress. Capital work in Progress comprises the direct expenditure on acquisition of property plant and equipment that are not yet ready for their intended use as at the balance sheet date. Other expenditure not relating to construction activity or incidental thereto is recognized in statement of profit and loss.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefit associated with the item will flow to the company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

If significant parts of an item of property plant and equipment have different useful lives, then they are accounted for as separate items (major components) of the said class of asset.

Depreciation

Depreciation is provided to write off the cost of property, plant and equipment over their estimated useful lives after taking into account their estimated residual value.

Depreciation is calculated using the written down value method to allocate their cost, net of their residual values, over their estimates useful lives. The depreciation methods, useful life and residual value, are viewed at each reporting date and adjusted prospectively.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e., from (up to) the date on which the assets is ready for use (disposed off). For the assets costing less than Rs.5,000, based on internal assessment and materiality the management has estimated that the same shall be depreciated in the year of purchase.

Gains and losses arising from derecognition of property plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

Derecognition:

An item of property , plant and equipment and any significant part initially

CONCORD DRUGS LIMITED

recognized is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the profit and loss when the asset is derecognized.

Impairment:

At each reporting date, management reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognized as an expense immediately. The recoverable amount of an asset is the greater of its value in use and fair value less cost to sell. Value in use is based on the estimated future cash flows., discounted to their present value using a pre tax discount rate that reflects current market assessments of the time value of money and risks specific to the asset.

d. Employee benefits:

i) Defined contribution plans:

The company pays provident fund contributions to publicly administered funds as per local regulations. The company is not regular in depositing the Provident fund amount. For details please refer point no-vii of the Annexure- A to the auditor's report.

ii) Defined benefit plan:

The company is required to provide for gratuity, defined benefit retirement plan covering eligible employees. However the company has not obtained Independent actuarial valuation to provide the liability in the books. The company has provided for the Gratuity liability on an Adhoc basis and hence the actuarial gains or loss is not effected in the Other Comprehensive Income of the statement of profit and loss.

Further the company has not provided for the liability towards the Leave encashment of the employees.

e. Borrowing costs:

Borrowing costs are interest and other cost incurred in connection with the borrowing of funds. General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required

CONCORD DRUGS LIMITED

to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. Other borrowing costs are expensed in the year in which they are incurred.

f. Earnings per share:

Basic earnings per share are calculated by dividing the profit attributable to the equity shareholders of the company by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential equity shares and the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

g. Financial Instruments:

i. Recognition and initial measurement

Trade receivables are initially recognized when they are originated. Trade receivables are measured on initial recognition at the transaction price. All other financial assets and financial liabilities are initially recognized when the company becomes party to the contractual provisions of the instrument. Further the Working Capital loans, Trade receivables and Trade payables carrying values presented in the financial statements approximate their fair values.

ii. Classification and subsequent measurement:

Financial assets

On initial recognition, a financial asset is classified as measured at

- Amortised cost
- FVOCI – Debt investment
- FVTPL – equity investment

Financial assets are not reclassified subsequent to their initial recognition, except if and in the year the company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the

CONCORD DRUGS LIMITED

following conditions and is not designated as at FVTPL

- The asset is held within business model whose objective is to hold assets to collect contractual cash flows; and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVTOCI if it meets both of the following conditions and is not designated as at FVTPL

- The asset is held within business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investments fair value in OCI (designated as FVOCI-equity investment). This election is made on an investment by investment basis.

Financial assets : Business Model assessment

The company makes an assessment of the objective of the business model in which a financial asset is held at portfolio level because this best reflects the way the business is managed and information is provided to the management. The information considered includes.

- how the performance of the portfolio is evaluated and reported to the Company's management
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about the future sales activity

CONCORD DRUGS LIMITED

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets. Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments for principal and interest.

For the purpose of this assessment, 'principal' is defined as the fair value of the financial assets on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- Contingent events that would change the amount or timing of cash flows;
- Terms that may adjust the contractual coupon rate, including variable interest rate features;
- Prepayment and extension features; and
- Terms that limit the Company's claim to cash flows from specified assets (e.g. on recourse features)

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract.

Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial

CONCORD DRUGS LIMITED

recognition.

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL: These assets are subsequently measured at fair value. Net gains and losses, including any interest and dividend income, are recognized in profit or loss

Financial assets at amortized cost:

These assets are measured at amortized cost using effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss

Debt investments at FVOCI:

These assets are subsequently measured at fair value. Interest income under effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.

Equity investments at FVOCI:

These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are not reclassified to profit or loss.

iii. Derecognition

Financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the company neither transfer nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the company enters into transactions whereby it transfers assets recognized on its balance sheet, but retains all or substantially all of the risks and rewards of the transferred asset, the transferred assets are not derecognized.

CONCORD DRUGS LIMITED

Financial liabilities

The company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. The company also derecognizes a financial liability when its terms are modified and its cash flows under the modified terms are substantially different. In this case, a new financial liability based on modified terms is recognized at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or loss.

Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

Impairment

The Company recognizes the loss allowances for:

- financial assets measured at amortized cost; and
- financial assets measured at FVOCI-debt investment

At each reporting date, the company assesses whether financial assets carried at amortized cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit impaired' when one or more events that have detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit –impaired includes the following observable data.

- Significant financial difficulty of the borrower or issuer,
- The restructuring of a loan or advance by the company on terms that the company would not consider otherwise;
- It is probable that the borrower will enter the bankruptcy or the financial reorganization; or
- The disappearance of an active market for a security because of financial difficulties

CONCORD DRUGS LIMITED

The company measures loss allowances at an amount equal to lifetime expected credit losses, except for the following which are measured as 12 month expected credit losses.

- Debt securities that are determined to have low credit risk at the reporting date; and
- Other debt securities and the bank balances for which credit risk (i.e the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowances for the trade receivable are always measured at an amount equal to expected lifetime credit losses. Life time expected credit losses are the credit losses that result from all possible default events over the expected life of a financial instrument.

Measurement and presentation of allowances for expected credit losses:

Expected credit losses are a probability- weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e the difference between the cash flows due to the company in accordance with the contract and the cash flows that the company expects to receive)

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is charged to profit or loss and recognized in OCI.

Write off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with company's procedures for recovery of amounts due.

h. Income Tax

Income tax comprises current and deferred tax. It is recognized in the statement of profit and loss except to the extent that it relates to a business combination or to an item recognized directly in equity or in other comprehensive income.

CONCORD DRUGS LIMITED

Current Tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set the recognized amounts, and it is intended to realize the asset and settle the liability on a net basis or simultaneously.

Deferred Tax

Deferred income taxes is recognized, subject to the consideration of prudence on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. Where the Company has carry forward of unabsorbed depreciation or tax losses deferred tax assets are recognized only if it is virtually certain backed by convincing evidence that such deferred tax assets can be realized against future taxable profits.

- i. Cash Flow Statement:
- i. Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents comprise cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank over drafts. Bank over drafts are shown within borrowings in current liabilities in the balance sheet.

- j. Measurement of earnings before interest, tax and depreciation (EBIDT)

As permitted by schedule III of the companies Act, 2013, the company has elected to present earnings before interest, tax and depreciation (EBIDT) as a separate line item on the face of the statement of profit and loss. The company measures EBIDT on the basis of profit/loss from continuing operations. In its measurement, the company has not included the depreciation expenses, finance cost, tax expense and other income.

CONCORD DRUGS LIMITED

k. Events occurring after the balance sheet date:

Impact of events occurring after the balance sheet date that provide additional information materially affecting the determination of the amounts relating to conditions existing at the balance sheet are adjusted to respective assets.

l. Contingent Liabilities and commitments :

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non- occurrence of one or more uncertain future events not wholly within the control of the group or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

m. Critical estimates and judgments:

The preparation of financial statements requires the use of accounting estimates and the management needs to exercise judgment in applying the accounting estimates and policies.

This note provides an overview of the areas that involved a higher degree of judgment or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be different than those originally assessed. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation for each affected line item in the financial statements.

2.1 Pending Litigations:

According to the information and explanations given to us, there are no material dues of sales tax, service tax and value added tax, wealth tax, duty of customs and cess which have not been deposited with the appropriate authorities on account of any dispute. However, accordingly to information and explanations given to us, the following dues of income tax, have not been deposited by the company on account of disputes.

Particulars	Demand U/S	Period to which The amount relates	Forum where the dispute is pending	Rs. in Lakhs	
				As at 31 st March 2020	As at 31 st March 2019
Income tax Act, 1961	143(3)	A.Y.2011-12	Commissioner of Income Tax (Appeals)-II	258.83	258.83
Income tax Act, 1961	143(3)	A.Y.2014-15	Commissioner of Income Tax (Appeals)-II	390.65	390.65

CONCORD DRUGS LIMITED

Note 3 : Fixed Assets
For the year (2019-20) Q4

Particulars	Gross Block			Depreciation /Amortization			Net Block	
	As at April 1, 2019	Additions	Deletion	As at March 31, 2020	Deletion during year	As at March 31, 2020	As at March 31, 2020	As at Mar 31, 2019
Land & Land Development	78,59,768			-	-	-	78,59,768	78,59,768
Sub-Total	78,59,768	-	-	78,59,768	-	-	78,59,768	78,59,768
Building	4,92,59,087			17,86,556		3,21,44,524	1,71,14,563	1,89,11,119
Furniture & Fixtures	40,00,630			2,80,357		31,98,110	8,02,520	10,82,877
Plant & Machinery	13,84,92,329	13,62,485		8,12,50,509	62,57,997	8,75,08,506	5,23,46,307	5,72,41,820
Office equipment	27,82,270	31,249		25,17,106	1,29,542	26,46,648	1,66,871	2,65,164
Vehicles	60,52,695			60,52,695	3,95,077	51,92,715	8,69,980	12,65,057
Air Handling Systems	3,59,17,595			3,59,17,595	19,78,192	2,69,86,551	89,51,044	1,09,29,235
Lab Equipment	3,04,05,609			2,02,03,586	18,46,566	2,20,50,152	83,55,457	1,02,02,023
Electrical Installations	2,99,18,049			2,04,13,703	17,20,287	2,21,33,990	77,84,059	95,04,346
Generator	35,68,140			24,28,367	2,06,299	26,34,666	9,33,474	11,39,773
Computers	1,70,030			79,854	28,162	1,08,016	62,014	90,176
Total	30,84,26,202	13,93,734	-	30,98,19,936	1,46,39,035	20,45,45,73,878	9,73,86,374	11,06,31,591
Capital Work-in Progress	28,88,941	70,88,316		99,77,257	-	-	99,77,257	28,88,941
	31,13,15,143	84,82,050	-	31,97,97,193	1,46,39,035	20,45,73,878	11,52,23,399	12,13,80,300

CONCORD DRUGS LIMITED

Notes forming part of the Financial Statements for the year ended 31st March ,2020

4. Other Non current assets

Rs. In Lakhs

PARTICULARS	31-Mar-20	31-Mar-19
(a) Capital advances		
Secured, considered good	39.29	36.28
Unsecured, considered good	-	-
Doubtful	-	-
Less: Provision for doubtful advances		
(b) advances to suppliers		
	39.29	36.28

5. Financial Assets

PARTICULARS	31-Mar-19	31-Mar-18
Loans and Advances		
(a) Security Deposits	5.05	5.05
Other Loans & Advances		
(b) Staff Advances	36.17	36.17
(c) Others	12.40	8.80
	53.62	50.02

CONCORD DRUGS LIMITED

6. Trade receivables

Rs. In Lakhs

PARTICULARS	31-Mar-20	31-Mar-19
a) Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	1,599.79	1,048.26
	1,599.79	1,048.26
Less: Provision for doubtful receivables	-	-
(I)	1,599.79	1,048.26
b) Others		
Unsecured, considered good	944.81	3,795.21
	944.81	3,795.21
Less: Provision for doubtful receivables		
(II)	944.81	3,795.21
Total Trade receivables (I+II)	2,544.60	4,843.47

7. Inventories

PARTICULARS	31-Mar-20	31-Mar-19
(Valued at lower of cost and net relisable value, unless stated other wise)		
(a) Raw materials and components	440.00	675.00
(b) Work-in-progress	403.51	455.23
(c) Finished goods	482.09	370.85
(d) Packing Materials	317.53	363.08
Total Inventories	1,643.13	1,864.15

CONCORD DRUGS LIMITED

8. Cash and bank balances

Rs. In Lakhs

PARTICULARS	31-Mar-20	31-Mar-19
Cash and cash equivalents		
Balances with banks		
(a) In current accounts	0.08	9.66
(b) Cash on hand	1.13	6.23
Total cash and cash equivalents	1.21	15.89
(c) Balances with banks other than above	2.59	2.59
Total Cash and bank balances	3.80	18.48

9. Other current financial Asset

PARTICULARS	31-Mar-20	31-Mar-19
(Unsecured, considered good, unless stated otherwise)		
(a) Security Deposits	4.13	4.13
(b) Other Advances (Imprest Cash)		
Total	4.13	4.13

10. Other Current Assets

PARTICULARS	31-Mar-19	31-Mar-18
(a) Advances to Suppliers	187.10	43.65
(b) Advance Tax	87.65	87.65
(c) TDS Receivable	0.63	0.55
(d) MAT Credit	69.34	69.34
(e) Other Current Assets	16.03	42.34
(f) Prepaid expenses	-	2.98
Total	360.75	243.53

CONCORD DRUGS LIMITED

Rs. In Lakhs

11. Equity Share capital

PARTICULARS	31-Mar-20	31-Mar-19
The Company has only one class of share capital having a par value of Rs. 10 per share, referred to herein as equity shares.		
<u>Authorised</u>		
1,10,00,000 (previous year 1,10,00,000) equity shares of Rs. 10/- each	1,100	1,100
<u>Issued, subscribed and paid up</u>		
8743750 (previous year 7861750) equity shares of Rs. 10/- each fully paid	874.38	786.18
Total	874.38	786.18

	31-Mar-20		31-Mar-19	
	No. of Shares	Amount in Rs.	No. of Shares	Amount in Rs.
(a) Reconciliation of shares outstanding at the beginning and at the end of the year				
Outstanding at the beginning of the year	78.62	786.18	78.62	786.18
Add: Issued during the year	8.82	88.20	-	-
Outstanding at the end of the year	87.44	874.38	78.62	786.18

(b) Rights, preferences and restrictions attached to shares

(i) The company has only one class of equity shares having par value of Rs. 10/- per share. Each shareholder is entitled to one vote per share held. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. (ii) During the year ended 31st March 2018, no dividend is recognized as distributions to equity shareholders. (iii) In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

CONCORD DRUGS LIMITED

(c) Shares held by holding company/ultimate holding company and/ or their subsidiaries/ associates

PARTICULARS	31-Mar-20	31-Mar-19
Name of the Holding Limited, the holding company (31st March 2018: No Holding Limited) equity shares of Rs. 10 each fully paid	Nil	Nil
Name of the ultimate holding company, the ultimate holding company (31st March 2018: No Ultimate Holding Company) equity shares of Rs. 10 each fully paid	Nil	Nil
Name of other Subsidiaries/Associate Company, subsidiary/ associate company (31st March 2018: No Subsidiary/Associate Company) equity shares of Rs.10 each fully paid	Nil	Nil
(d)Aggregate number of bonus shares issued, shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting date:	Nil	Nil
Equity shares allotted as fully paid bonus shares by capitalization of securities premium		
Equity shares allotted as fully paid-up pursuant to contracts for consideration other than cash		
Equity shares bought back by the company	Nil	Nil

(e) Details of shares held by shareholders holding more than 5% of the aggregate shares in the Company

	31-Mar-20		31-Mar-19	
	Number of shares	% of holding in the class	Number of shares	% of holding in the class
Koni Reddy Seelam	9.75	11.15%	7.97	10.14%
Nagi Reddy Seelam	17.03	19.48%	14.13	17.97%
S.Manoj Reddy	6.65	7.61%	4.51	5.74%
Vundela Rama Subba Reddy	3.975	4.55%	3.975	5.06%

As per records of the company, including its register of shareholders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

CONCORD DRUGS LIMITED

12 Reserves and surplus

Rs. In Lakhs

PARTICULARS	31-Mar-20	31-Mar-19
(a) Capital Reserves		
Opening balance	41.00	41.00
Add: Current year transfer from		-
Less: Utilisation on account of / Transfer to	-	-
Closing balance	41.00	41.00
(b) Surplus/(deficit) in the Statement of Profit and Loss		
Opening balance	830.26	789.55
Add: Net Profit/(Net Loss) for the current year	32.83	40.70
Transfer from reserves		
Transfer to reserves	-	-
Closing balance	863.08	830.26
(c) Securities premium		
	570.00	234.84
Total Reserves and surplus	1,474.08	1,106.10
Other equity Unsecured Loans from Directors are grouped as Other equity	-	423.36
Total Other equity	1,474.08	1,529.46

CONCORD DRUGS LIMITED

Rs. In Lakhs

Non Current Liabilities

13. Financial Liabilities - Borrowings

PARTICULARS	31-Mar-20	31-Mar-19
Secured		
(a) Term loans		
from banks	-	-
(b) Interest Free Sales Tax Loan	65.43	65.96
Unsecured		
(a) Loans and advances from related parties	22.30	3.01
Total long term borrowings including its current maturities	87.72	68.97
Less: Amount disclosed under the head "Other current liabilities" (refer note 18)	-	-
Total current maturities of long term borrowings	87.72	68.97
Un secured loan from Directors Grpd as Other equity	-	-
Adjustment of Interest Free Sales Tax loan (recognised as Government Grants)	-45.53	-54.13
Total	87.72	68.97

14 Deferred tax liabilities / (asset) (Net)

PARTICULARS	31-Mar-20	31-Mar-19
Opening Deferred Tax Liability	12.79	21.23
For The Year	0.91	-8.44
Total	13.70	12.79

CONCORD DRUGS LIMITED

Rs. In Lakhs

15. Provisions

PARTICULARS	31-Mar-20		31-Mar-19	
	Long term	Short term	Long term	Short term
(a) Provision for Creditor for Capital Expenses	-	-	-	-
(b) Other provisions (Specify nature)	-	-	-	-
Provision for Income tax	198.88	11.91	207.73	11.72
Provision for gratuity	9.50	-	9.50	-
Total Provisions	208.38	11.91	217.23	11.72

16. Borrowings

PARTICULARS	31-Mar-20	31-Mar-19
Secured		
(a) Loans repayable on demand from banks	869.10	913.68
Total Short -term borrowings	869.10	913.68

17. Trade payables

PARTICULARS	31-Mar-20	31-Mar-19
Non Current		
Trade payables	377.49	2,631.62
Current		
(a) Trade payables	902.13	1,632.11
Total	1,279.62	4,263.73

18. Other current Financial Liabilities

PARTICULARS	31-Mar-20	31-Mar-19
Current maturities of long-term debts	-	-
Total	-	-

CONCORD DRUGS LIMITED

19. Other current liabilities

Rs. In Lakhs

PARTICULARS	31-Mar-20	31-Mar-19
(a) Provision for Expenses	297.16	288.17
(b) Advance Received from Customers	429.16	111.60
(c) Advance for Capital Assets	191.00	-
(c) ESI,PF, Other taxes Payable	13.90	13.90
(d) Unpaid dividends		-
(e) TDS Payable	5.90	5.30
Total	937.13	418.96

20. Revenue from operations

PARTICULARS	31-Mar-20	31-Mar-19
Sale of products		
Finished goods	5,133.89	4,807.72
Revenue from operations (Gross)	5,133.89	4,807.72
Less: Excise duty	-	-
Total	5,133.89	4,807.72

21. Other income

PARTICULARS	31-Mar-20	31-Mar-19
Interest income	0.80	0.70
Miscellaneous income	0.20	0.27
Interest from Govt Grant	8.61	7.61
creditors written off	2.40	-
Total	12.01	8.59

CONCORD DRUGS LIMITED

Rs. In Lakhs

22. Cost of raw material consumed

PARTICULARS	31-Mar-20	31-Mar-19
Raw material consumed		
Inventory at the beginning of the year (Includes Goods in transit)	675.00	823.76
Add : Purchases during the year	2,488.85	2,781.51
Less: Inventory at the end of the year (Include Goods-in transit)	440.00	675.00
Cost of raw material consumed (I)	2,723.85	2,930.27
Packing material consumed (if considered as part of raw material)		
Inventory at the beginning of the year [Include Goods-in transit]	363.08	55.87
Add : Purchases during the year	1,547.85	1,177.94
Less: Inventory at the end of the year [Include Goods-in transit]	317.53	363.08
Cost of packing material consumed (II)	1,593.40	870.73
Finished Goods Consumed		
Inventory at the beginning of the year [Include Goods-in transit]	370.85	481.49
Add : Purchases during the year	-	2.21
Less: Inventory at the end of the year [Include Goods-in transit]	482.09	370.85
Cost of other material consumed (III)	-111.24	112.85
Total raw material consumed (I+II+III)	4,206.02	3,913.85

CONCORD DRUGS LIMITED

23. Changes in inventories of finished goods, work in progress and stock-in trade

Rs. In Lakhs

PARTICULARS	31-Mar-20	31-Mar-19
Inventories at the beginning of the year:		
Work in progress	455.23	500.82
(I)	455.23	500.82
Inventories at the end of the year:		
Work in progress	403.51	455.23
(II)	403.51	455.23
(Increase)/decrease in inventories of finished goods, work-in-progress and stock-in-trade	51.72	45.59

24. Employee benefits expense

PARTICULARS	31-Mar-19	31-Mar-18
Salaries, wages, bonus and other allowances	322.22	221.32
Directors Remuneration	24.00	24.00
Contribution to provident and other funds	-	3.53
Staff welfare expenses	4.49	4.07
Total	350.72	252.92

25. Finance cost

PARTICULARS	31-Mar-20	31-Mar-19
Interest expense		
On bank loan	144.60	149.47
Other borrowing costs	-	0.06
Bank charges	1.16	2.15
Interest on VAT loan	8.61	7.61
Total	154.37	159.30

CONCORD DRUGS LIMITED

26. Other Expenses

PARTICULARS	31-Mar-19	31-Mar-18
Consumption of stores and spare parts	12.46	1.95
Power and fuel	76.79	77.73
Repairs and maintenance		-
Buildings	3.03	6.90
Plant & machinery	4.96	19.75
Others	2.06	0.55
Vehicle Maintenance	13.28	11.21
Insurance	6.90	7.54
Listing Fees	3.00	2.50
Auditor's remuneration	1.50	3.50
Business Promotion Expenses	11.20	11.33
Duties and Taxes	4.71	0.16
Travelling, Boarding & Lodging Expenses	1.38	1.27
Freight & Transportation Expenses	10.77	7.08
Postage & Courier Charges	0.71	0.51
Legal & Professional Charges	7.53	3.60
Printing & Stationery	5.52	5.77
Registration & Renewals	11.52	3.85
Telephone Charges	1.05	1.37
Factory Maintenance Expenses	6.43	4.47
Debits written off/credits written back (Net)	-	54.24
Miscellaneous	3.51	4.22
Security Chargers	2.73	-
Total	191.03	229.50

CONCORD DRUGS LIMITED

2.2 Auditor's Remuneration:

Professional and consultancy charges includes the remuneration paid (including service tax) to auditors as follows:

Rs. In Lakhs

PARTICULARS	As at 31 March 2020	As at 31 March 2019
Statutory audit fees	3.00	3.00
Limited review fees	0.00	0.00
Tax audit fees	0.50	0.50

2.3 Details of dues to Micro and Small enterprises as defined under the MSMED Act, 2016

The Management has identified enterprises which have provided goods and services of the company and which qualify under the definition of Micro and Small enterprises, as defined under Micro and Small Enterprises Development Act, 2006.

Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2019 has been made in the financial statements based on information received and available with the company. Further in the view of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Act is not expected to be material.

The company has not received any claim for interest from any supplier under the said Act.

SI no	Particulars	Rs. in Lakhs	
		31-Mar-20	31-Mar-19
a)	The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting period;	NIL	NIL
b)	The amount of interest paid by the Company along with the amounts of the payment made to the supplier beyond the appointed day during the period;	NIL	NIL
c)	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act;	NIL	NIL
d)	The amount of interest accrued and remaining unpaid at the end of the period;	NIL	NIL
e)	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under the MSMED Act, 2006	NIL	NIL

CONCORD DRUGS LIMITED

2.4 Related party disclosures:

a) Names of related parties and nature of relationship:

Subsidiary Companies	NIL
Companies controlled by key management Personnel/ relatives who are substantially interested	Cortex Laboratories Pvt Ltd, Proton remedies Pvt Ltd , Austrazen Bio Pharmaceuticals pvt Ltd
Key managerial personnel	Nagireddy Seelam (MD) Konireddy seelam
Directors	Tathireddy Narsimha reddy Chandrakala Panthamvar Jyoti Goyal

b) Related parties transactions during the year:Rs. in Lakhs

Details	Associate Companies / Concerns	Key Management Personnel	Associate Companies / Concerns	Key Management Personnel
	2019-20 Rs.		2018-19 Rs.	
Remuneration	-	24.00	-	24.00
Sales	256.90	-	902.46	-
Purchase of Raw material	361.87	-	1318.65	-
Unsecured loans (net)				
S. Nagireddy	9.97		0.05	
S. Koni Reddy	0.00		1.30	
S Manoj Kumar	0.13		0.18	

CONCORD DRUGS LIMITED

c) Related party balances at the end of the year:

Details	Associate Companies / Concerns	Key Management Personnel	Associate Companies / Concerns	Key Management Personnel
	2019-20 Rs.		2018-19 Rs.	
Remuneration Payable	-	25.26	-	19.28
Cortex laboratories Pvt Ltd.	89.09		2269.59	-
S Nagi Reddy	9.98		0.05	
S Koni Reddy	0.00		1.30	
S. Manoj Reddy	0.31		0.18	

2.5. Earnings Per share (EPS):

The computation of earnings per share is set out below

(Amount in Rs.)

PARTICULARS	Year ended 31st March 2020	Year ended 31st March 2019
Earnings (Amt in Rs.):		
Profit/Loss as per the statement	32.83	40.70
Shares:		
Number of shares at the beginning of the year	87.44	78.62
Total number of equity shares outstanding at the end of the year	87.44	78.62
Weighted average number of equity shares outstanding during the year-Basic and Additional	87.44	78.62
Earnings per share in Rs. Par value Rs.10 per share:		
Basic and diluted	0.38	0.52

CONCORD DRUGS LIMITED

2.6 Income taxes relating to continuing operations:

Income tax recognized in profit or loss

Rs. in Lakhs

PARTICULARS	Year ended 31st March 2020	Year ended 31st March 2019
Current tax		
In respect of the current year	11.91	11.72
In respect of the prior year	-	-
	11.91	11.72
Deferred Tax		
In respect of the current year	0.91	(8.44)
	0.91	(8.44)

2.7 Segment Reporting:

The Company is engaged in the manufacture of pharmaceutical Formulations.

(Amount in Rs.)

PARTICULARS	Total
Sales	5133.89
Profit before interest & Depreciation	346.41
Depreciation	146.39
Interest	154.37
Profit Before Tax	45.65
Taxes	12.82
Profit After Tax	32.83

CONCORD DRUGS LIMITED

2.11 Previous year figures have been regrouped/ reclassified wherever if thought necessary in conformity with the current year groupings. Paise have been rounded off to the nearest rupee. Notes on financial statements, Cash Flow Statement and statement on accounting policies form an integral part of the balance sheet and statement and statement of profit & loss.

For N.G Rao and Associates
Chartered Accountants
FRN- 009399S

G. Nageswara Rao
Partner
Mno-207300

Place: Hyderabad
Date: 27/06/2020

For and on behalf of the Board of Directors of
Concord Drugs Limited

Sd/-
S. Nagi Reddy
Chairman and Wholetime Director
DIN:01764665

Sd/-
Koni Reddy Seelam
Executive Director cum CFO
DIN: 02829319

Sd/-
Jyoti Goyal
Company Secretary

If Undelivered, please return to:

CONCORD DRUGS LIMITED

Survey No.249, Brahmanapally Village

Hayatnagar Mandal R.R.Dist-501511

Telangana, India.